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EXECIJTTVE SUMMARY 
In 1991 the lllawarra Pharmacists Association in conjunction with the lllawarra 
Public Health Unit and the University of Wollongong Department of Mathematics 
undertook the Pharmacy Exit Survey. This was a cross-sectional survey 
administered to purchasers of anti-asthma medications throughout community 
pharmacies in the lllawarra. This survey was repeated in 1995 allowing evaluation 
of improvements in adult asthma between 1991 and 1995 possibly due to local and 
national initiatives. 
Indicators of asthma management are described in terms of the National Asthma 
Campaign recommendations. These parameters are compared between those 
obtaining their p-agonists primarily over the counter and those who obtain them 
primarily by prescription, as well as analysing changes between the 1991 and 1995 
samples. Potential confounders such as age, sex and severity indicators were 
controlled for using the stepwise logistic regression procedure. Crude prevalence 
estimates of asthma management factors were weighted using data from a second 
study utilising routinely collected drug prescription information, in an attempt to 
adjust for the potential bias from an oversampling of those who purchased their 
medications more frequently. 
Of the respondents 35.4 percent reported primarily obtaining |3-agonist inhalers 
over the counter. The prescription group had more severe asthma than the 'over 
the counter' group. The 'over the counter' group was less likely to wheeze at least 
once per week (P=0.005, OR=0.59, CI=0.39-0.96), to have had at least five attacks 
of asthma or wheeze in the last year (P=0.001, OR=0.54, CI=0.35-0.80), to have 
been admitted to hospital within the last 12 months (P=0.002, OR=0.31, Cl=0.16-
0.62), and to use a p-agonist inhaler at least daily (P=0.004, OR=0.64, Cl=0.42-
0.99). 
Even after taking into account differences in disease severity, the 'over the counter' 
group was less likely to have objective airways measurement by the doctor usually 
or always (P=0.007, OR=0.37, CI=0.21-0.67), to have a written action plan 
(P=0.008, OR=0.48, CI=0.26-0.88) and to have regular medical review at least once 
per year (P=0.001, OR=0.50, CI=0.27-0.93). The 'over the counter group' was also 
less likely to use preventative medication (P=0.001, OR=0.29, Cl=0.16-0.51) or 
ipratropium bromide (P=0.001, OR=0.27, CI=0.09-0.88) regularly during the 
previous six months, and less likely to use inhaled corticosteroids (P=0.004, 
OR=0.35, Cl=0.21-0.61), and ipratropium bromide (P=0.001, OR=0.44, Cl=0.20-
0.94) at any time. 
Between 1991 and 1995 there was no significant improvement in non-drug related 
asthma management indicators. Prescribing patterns improved with increases in the 
regular use of inhaled corticosteroids or sodium cromoglycate (P=0.001, OR=0.87, 
CI=0.80-0.95) and an increase in the use at any time of sodium cromoglycate 
(P=0.033, OR=0.87, Cl=0.80-0.95). The use of medications which may be 
inappropriate for asthma (eg. antibiotics), are still prevalent however there has been 
a reduction in the use of theophylline both regularly (P=0.001, 0R=1.27, Cl=1.14-
1.41) and at any time (P=0.001, 0R=1.27, Cl=1.15-1.40). These improvements in 
prescribing are in line with the recommendations of the Asthma Management Plan. 
Improvements in asthma management however are sub-optimal, particularly in 
relation to the 'over the counter' group. Targetted local initiatives are needed to 
improve adult asthma management in the lllawarra region, supporting programs 
from the National Asthma Campaign and any state-wide initiatives. 
1. INTRODUCTION 
There has been a number of local programs in the lllawarra which were aimed at 
improving asthma management. The first of these involved 94 per cent of community 
pharmacies in a regional research program which aimed to identify barriers to asthma 
management and problems implementing the "Pharmacists Asthma Management Plan". 
Several interested pharmacists then participated in focus groups to further examine the 
issue, and were finally brought together with a group of lllawarra general practitioners 
to examine common problems.^ 
The National Asthma Campaign began in 1990, with the first phase concentrating on 
health professionals: doctors, pharmacists, nurses and ambulance officers.^ The 
National Asthma Campaign produced and mailed 28 000 detailed educational booklets 
to general practitioners across Australia, together with information pamphlets for 
patients and cards to aid doctors in producing individualised action plans for their 
patients. The National Asthma Campaign also took out more than 30 two page 
advertisements in the most frequently read medical journals promoting the Asthma 
Management Plan, the use of peak flow meters and preventative medications.^ 
The second phase of the campaign was directed at the asthma sufferer and aimed to 
increase knowledge about asthma and health lifestyle. This phase consisted of an 
education program run through schools, unions and employer groups and distribution 
of the Asthma Management Plan through health care providers.'^ 
The third phase in mid 1991 was a major asthma awareness media campaign directed 
at the general public. It aimed to inform the general community of the limitations of 
using inhaled bronchodilator medication to treat asthma. This phase of the campaign 
was based around a 30 second television public service announcement. This depicted 
a colourless male robotic figure who repetitively overuses bronchodilator medication 
untill he hears a new message about asthma management. He aquires an asthma 
action plan and becomes more human. The final message states that people should 
turn to their health professional to learn prevention, leading to a symptom free life.® 
Few studies have examined asthma management in the Australian community. These 
surveys give some indication of the effect of both local and national initiatives in asthma 
management. They provide the basis for objective measurement of application by 
health professionals and acceptance by consumers of National Asthma Campaign 
guidelines. The baseline measurement in 1991 showed areas of sub-optimal asthma 
management and the analysis of both the 1991 and 1995 data will give an assessment 
of changes in practice over this time frame. 
2. BACKGROUND 
Asthma is defined as a chronic inflammatory condition of the airways characterised by 
bronchial mucosal inflammation, with oedema, infiltration with inflammatory cells 
(especially eosinophils), hypertrophy of glands and smooth muscle and damaged 
epithelium. Symptoms include wheezing, coughing, chest tightness and shortness of 
breath. This condition may lead to irreversible obstruction of air flow in some chronic 
patients.®'"̂ ® 
Asthma is a significant problem in Australia both in terms of mortality and morbidity as 
well as cost to the Australian community.®'̂ ® In 1991 the total cost burden of asthma in 
Australia was estimated to be between $585 and $720 million. This comprised of $320 
million of direct medical costs and between $260 and $400 million indirect costs. 
Indirect costs are those due to lost productivity to society due to asthma. It includes the 
costs of invalidity, absenteeism, reduced effectiveness whilst at work, and work time 
lost from attending appointments. The direct medical costs are made up of general 
practitioner time, medication, specialist time, emergency attendances, hospital 
outpatient and inpatient services.^^ Asthma is also one of the most common causes of 
admission to hospital. Asthma is a high priority on the health agenda because it is a 
largely manageable disease. Well managed sufferers can usually lead perfectly normal 
lives. 
The 1989-90 National Health Survey run by the Australian Bureau of Statistics 
estimated that 1.4 million or between 8-9 per cent of all Australian are clinically 
diagnosed asthmatics.^^ This finding was supported by a National Asthma Campaign 
baseline survey which estimated prevalence in adults aged 12 and over to be 7 per 
cent.^^ Bauman ef a/in a survey of a stratified random sample of schoolchildren and 
their parents from schools in Sydney, Melbourne, Brisbane and the Upper Hunter 
Valley (New South Wales) found 19 percent of adults reporting wheeze symptoms in 
the previous 12 months and 7.2 per cent had diagnosed asthma.""^ A repeat of this 
survey in 1993, found no significant change in reported wheezing or in diagnosis of 
asthma in adults.̂ ® 
The National Asthma Campaign was initiated in 1989 with the aim of improving asthma 
management through promotion of a recognised Asthma Management Plan which was 
devised by the Thoracic Society of Australia and New Zealand.^® The latest revision 
of the Asthma Management Plan was published in 1993 by the National Asthma 
CampaignJ^ This approach is widely recommended however it has not been 
unequivocally shown to lead to improved asthma control.^® 
The Asthma Management Plan is made up of six clear steps which can be followed by 
clinicians. It draws on evidence that many asthma deaths are associated with under 
treatment related to an over-reliance on bronchodilators and under use of inhaled and 
oral corticosteroids, failure to make objective measurement of disease severity and 
inadequate supervision.''®'̂ '̂̂ '̂̂ '̂ ^ Regular use of inhaled corticosteroids is emphasised 
in the Asthma Management Plan, even for those patients of moderate disease severity. 
Inhaled corticosteroids are extremely important as they act directly on the airways to 
reduce inflammation and bronchial hyper responsiveness, p-agonists on the other 
hand can only alleviate the symptoms of asthma and do nothing to alter the underlying 
disease process.^"^ Sears et al found in a double blinded, placebo-controlled, 
randomised crossover study that regular inhalation of p-agonist drugs was associated 
with a deterioration of asthma control in the majority of subjects compared with p-
agonist use for symptom relief only.^^ 
Written action plans are also a very important component of the Asthma Management 
Plan as an inability to recognise deteriorating asthma has been suggested as an 
important preventable factor in asthma d e a t h s . A s t h m a self management plans 
are essential in the long term management of adult asthmatics because they help 
people to recognise deteriorating asthma and initiate early and appropriate treatment.^^ 
Charlton et al have challenged the need for a peak flow meter in order to implement 
self management plans. They tested through a randomised follow-up trial two self 
management plans, the first measuring peak expiratory flow and the second based 
purely on symptoms. Both self management plans produced significant reductions in 
the measured outcomes, however there were no significant differences between the 
groups using the different plans. It was concluded that the peak flow meter was not the 
crucial ingredient in the decreasing morbidity of the two groups of asthmatics and that 
teaching patients the importance of their symptoms and the appropriate action to take 
when their asthma deteriorates is the key to effective management of asthma.̂ ® 
Step 1 of the Asthma Management Plan involves assessing the overall severity of the 
disease. Step 2 deals with achieving the best possible lung function. Step 3 involves 
maintaining that best possible lung function through home monitoring of peak expiratory 
flow, drug therapy and avoidance of trigger and aggravating factors. Step 4 is 
concerned with developing an action plan including recognising indicators of worsening 
asthma, developing the written crisis plan and knowing how best to seek medical help. 
This action plan should be reviewed after attacks. Step 5 deals with educating, 
supporting and counselling the patient and family, and step 6 encourages regular 
review of the patient. 
Because of the very high prevalence of asthma, the condition is often managed in the 
primary health care setting by general pract i t ioners^^and by pharmacists. Tse et 
al in 1991 found that most general practitioners around Australia knew and reported 
practicing appropriate asthma management, however room for improvement was found 
in regards to the understanding and use of theophyllines, the use of preventative 
medications such as inhaled steroids and sodium cromoglycate, the use of crisis 
planning for severe attacks and lung function measurement.̂ "^ Fardy and Jeffs in the 
lllawarra found asthma knowledge of general practitioners to be very high, with 88 per 
cent of general practitioners scoring more than 86 per cent on a test.^^ The results of 
a "subsample" of lllawarra general practitioners from a national general practitioner 
survey^® showed reported management practices were generally of a high standard, 
however they were not entirely consistent with the Asthma Management Plan, lllawarra 
general practitioners were no different to those of the national sample. The results 
suggested that lllawarra general practitioners were inappropriately prescribing 
theophyllines and that inhaled steroids and sodium cromoglycate were being 
underused as preventative medications. Only 40 per cent of lllawarra general 
practitioners were developing written crisis plans for patients and only 36 per cent 
reported measuring airways function at most visits.^^ Beilby ei a/found no significant 
differences in methods of treatment of adults with asthma between city and country 
general practitioners.^® 
The National Asthma Campaign was effective in making general practitioners aware 
of the principles of good asthma management. As mentioned earlier, the first stage of 
the campaign basically consisted of a mail out package to general practitioners of 
information and aids to good management as well as a series of advertisements in 
medical journals promoting the principles of the Asthma Management Plan. After the 
campaign general practitioners reported significant improvements in ainA/ay function 
measurement practices, the use of preventative drug therapy and the use of written 
action plans.̂ ® A population based approach has also been taken in evaluating the 
National Asthma Campaign. After the campaign there was an increase in the use of 
inhaled corticosteroids and a decrease in the use of theophyllines. Measurement of 
lung function by a doctor in the previous year, ownership of a peak flow meter, and 
possession of a written action plan all increased."^ All of these changes are in line with 
the Athma Management Plan."̂ ^ 
It has also been suggested that the Asthma Management Plan may not be appropriate 
or feasible for general practitioners as it was written by specialist respiratory 
physicians, and there are differences between the spectrum of patients and severity of 
diseases encountered by specialists and general practitioners'̂ '̂̂ ^. Kelly et al in a study 
of community pharmacists in the lllawarra found that pharmacists also had problems 
implementing the "Pharmacists Asthma Management Plan". Aspects of the plan which 
pharmacists had most difficulty implementing were ensuring people with asthma had 
a written action plan, identifying undiagnosed asthmatics, ensuring people with asthma 
know why and how a peak flow meter is used, and advising on identification and 
avoidance of trigger factors. Barriers were identified to improved asthma management. 
These included a lack of time, a lack of renumeration for counselling, and a customer 
attitude of reluctance to discuss their condition and a primary lack of awareness of the 
need for preventative medication. Aspects of the plan pharmacists had least difficulty 
implementing included ensuring an understanding of the difference between 'reliever' 
and 'preventer* medication, ensuring correct inhaler technique, identifying and referring 
frequent users of p-agonists, and emphasising and assisting with compliance/"^ 
In 1975 salbutamol, terbutaline and feneterol were moved from schedule 4 (prescription 
only) to schedule 3 (available from a pharmacists without a prescription) in NSW with 
other states doing the same through to 1983. The benefits of such a move included a 
financial gain for the community because of a reduction in asthmatics consulting a 
doctor just for a script as well as making these reliever medications easily accessible 
to the community. Potential risks included: and increase in unsupervised use of (3-
agonist aerosols; reduced access to education about asthma; delays in seeking 
essential treatment for worsening asthma, and a development of excessive 
dependence on them limiting the use of other drugs which can only be obtained with 
a prescription."^® Jenkins et al in a study of data of prescribed antiasthmatic drugs 
reported that non-prescription sales of salbutamol inhalers increased 410 per cent from 
1980-6.^® 
An important issue in the current management of asthma is the potential problems 
associated with overuse of p-agonists. Sears ef a/compared the control of asthma 
during two regimes of fenetorol use. In most cases, control of asthma was less 
effective with regular use of high doses of feneterol than with use as dictated by 
necessity."^^ Haahtela et al found that antiinflammatory therapy with inhaled 
budesonide (inhaled corticosteroid) to be an effective first-line treatment for patients 
with newly detected, mild asthma. It was found to be superior to the use of terbutaline 
(P-agonist) in such patients."̂ ® 
Henry ef a/compared asthmatics aged 13-55 years in the Hunter Valley region of New 
South Wales who either used purchase as their sole means of acquiring metered dose 
inhalers and used no prescription medication, or who used a prescription to obtain 
some or all of their asthma drugs. Of all salbutamol inhalers dispensed, 40 per cent 
were purchased over the counter. They found 97.5 per cent of the purchase group 
were undertreated, in that they required either inhaled or oral steroids and 47 per cent 
of the prescription group received inadequate treatment. They also found that the 
purchase group "seldom" visits the doctor (general practitioners or specialists). They 
concluded that the present scheduling of P-agonists continues to legitimise the 
unsupervised use of bronchodilater aerosols as a sole treatment by significant numbers 
of asthmatics in Australia.'^^ 
Marias ef a/in a study of asthmatics in Lismore, New South Wales in 1994, found that 
many participants with moderate or severe asthma were not managed in accordance 
with the recommendations of the asthma management plan. In particular small 
proportions took inhaled steroids, used a peak flow meter or had a written action plan. 
Excess use of p-agonists were not however found to be a significant problem^® 
Westley-Wise ei a/(1991) found in a review of pharmacy databases in the lllawarra, 
that of those prescribed an average of more than 6 inhalations of p-agonists daily, 19 
per cent were not prescribed any preventative medications and 36 per cent were 
prescribed an average of less than 2 inhalations of preventative medication daily.^^ 
This represented relatively poor drug therapy in the overall management of asthmatics 
in the area. They estimated that at least 40 per cent of asthmatics were receiving 
inadequate doses of inhaled preventative medications. 
A study of 434 adult P-agonist purchasers in the lllawarra in 1991 found that 39 per 
cent purchased their p-agonist medications primarily over the counter.^^ The over the 
counter group was younger, and less likely to report regular peak flow measurement 
by the doctor. The group mostly obtaining their p-agonists medicators by prescription 
was more likely to have regular routine medical review, and more likely to use inhaled 
preventative medication regularly. They also found significant use of medications 
which may be contraindicated for people with asthma, including the use of 
theophyllines without the use of inhaled corticosteroids which the Asthma Management 
Plan®^ specifically advises against. 
3. RESEARCH QUESTIONS 
The aim of the Pharmacy Exit Survey is to identify current asthma management 
practices in terms of utilisation of: 
preventative medication and p-agonists, 
medications which may be contraindicated for people with asthma, 
peak flow meters for self-monitoring and monitoring by doctors, 
written management plans, and 
routine medical review. 
It is also aimed to compare indicators of disease severity and appropriateness of 
asthma management practices between those who predominantly obtained their p-
agonist inhalers over the counter (the OTC group) and those who obtained them mainly 
by prescription (the prescription group). 
The aim of the Drug Utilisation Survey is to provide information related to the 
prescribed medication obtained by users of anti-asthma medications in the lllawarra 
including: 
• preventative medications and p-agonists, and 
• medications which may be contraindicated for people with asthma. 
For the purpose of this study, the Drug Utilisation Survey aims to provide information 
of the frequency of visits to community pharmacies to have prescriptions filled for p-
agonists and the frequency of visits for all anti-asthma medications. These measures 
are used to weight prevalence estimates of asthma management factors to adjust for 
the potential over sampling of those who more regularly obtain anti-asthma medications 
from community pharmacies. 
These surveys were first carried out in 1991 by the lllawarra Pharmacists Association 
in conjunction with the lllawarra Area Health Service Public Health Unit and the 
University of Wollongong Department of Mathematics. The results of these surveys are 
reported elsewhere.®"̂ -®® 
These surveys were repeated in 1995. The aim is to analyse changes in asthma 
management practices between 1991 and 1995 which may be due to local or national 
initiatives which occurred during this period. 
11 
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4 . M C T H O D S 
A literature search was carr ied out using MEDLINE database f rom years 1990 to 1996 
a n d C I N A H L (Nurs ing and Al l ied Health) da tabases from years 1982 to 1996. Key 
search terms included asthma, management, adult and Austral ia. References f rom the 
resu l ts of the or ig ina l search were used to extend searches. Literature was also 
ob ta ined f rom a rea heal th serv ice reports and local publ icat ions. 
The same methodology w a s used in 1995 as in 1991, except for slight changes to the 
ques t ionna i re , a n d minor d i f ferences in the methods of analysis from the or iginal 
study.®® Repor ted here are the results of identical analysis of both 1991 and 1995 
Pharmacy Exit Survey data, except in relation to question 13 which was added in 1995. 
All pha rmac ies (66) in the l l lawarra area were asked to part icipate. Each pharmacist 
was asked to recnj i t 12 consecut ive cl ients aged 15 years or over obtaining any anti-
asthmatic medicat ions (P-agonists, theophyl l ines, inhaled cort icosteroids, ipratropium, 
or s o d i u m cromog lyca te) to fill in the one page quest ionnaire. Each pharmacist 
completed a data sheet including: the gender and age (est imated for non-responders) ; 
the i r answe rs to two quest ions der ived from a previously val idated questionnaire®^ 
(concerned wi th prev ious as thma d iagnosis and chronic sputum product ion); and 
whe the r they ag reed or refused to complete the quest ionnaire. The quest ions 
concerned with sputum production and asthma diagnosis were used to exclude people 
with chronic bronchit is (defined as reporting chronic sputum product ion and never been 
d iagnosed with as thma) at the da ta analysis stage. 
T h e 1991 and 1995 part ic ipant informat ion sheets and quest ionnai res are shown in 
append i ces 2 a n d 3 respect ively. The quest ionnaires include quest ions related to 
a s t h m a m a n a g e m e n t pract ices such as use of peak f low meters, wri t ten plans, 
medicat ion, and medica l superv is ion. Also included are quest ions related to as thma 
severity such as frequency of wheezing and "attacks" of as thma and wheeze, previous 
hospital isation, and f requency of use of p-agonist inhalers. In addit ion there was one 
quest ion about the f requency of visits to communi ty pharmac ies to obtain ant i -asthma 
medications. The questionnaire was altered slightly from 1991 to 1995. Changes were 
made in Question 1 and Question 11 due to changes in the availability of brand name 
dnjgs, as well as other minor changes in question expression. Slight wording changes 
can also be noted in Question 3 and Question 7. These wording changes were 
unintentional, however they are not expected to influence the responses in any manner. 
Question 13, which related specifically to the frequency of visiting community 
pharmacies to have scripts filled for p-agonists, was also added to the questionnaire 
in 1995. Question 12, which is primarily used for weighting the asthma management 
prevalence estimates, obtains the frequency of pharmacy visits to obtain medication 
"for your chest". The corresponding Information from the Drug Utilisation Survey 
measures the frequency of visits to community pharmacies to have prescriptions filled 
for either all anti-asthma medications or for p-agonist medications. Question 13 
therefore is a more specific question which collects information which is more 
appropriate for the weighting methodology used. 
The data were entered into Epilnfo v5.1. The data were analysed using SAS v6.10 for 
Windows. Prevalence estimates were made of indicators related to asthma severity 
and asthma management. Crude odds ratios are used to compare severity and 
asthma management indicators between groups who reported mainly obtaining P-
agonists over the counter or mainly by prescription in 1995 and between the 1991 and 
1995 groups. Statistical significance was established by means of the Chi-squared 
test. Confidence limits of the crude odds ratios were calculated by the methods of 
Cornfield using Epilnfo v6.0.̂ ® 
The cnjde odds ratios for potential measures of disease severity were adjusted for age 
and sex by logistic regression analysis. The crude odds ratios for asthma management 
indicators were adjusted for potential confounders such as age, sex and severity using 
stepwise logistic regression analysis. Indicators of disease severity controlled for in the 
analysis were frequency of wheezing (categorised as at least weekly, at least most 
days, and at least daily), frequency of asthma attacks (categorised as at least five and 
at least 10 in the last year), frequency of pharmacy visits to obtain "chest" medication 
(categorised as at least once in the last 12 months, at least 3-4 times, at least 5-10 
times, at least 11-25 times and more than 25 times), previous hospitalisation 
(characterised as ever and within the last year), and frequency of inhaler use 
(characterised as at least once a week, a few times per week, once a day, five times 
a day, and more than ten times a day). The logistic regression analyses were also run 
without including frequency of inhaler use as an indicator of disease severity. 
Statistical significance are shown at the 0.05 level with 95 per cent confidence limits. 
In order to adjust prevalence estimates for the potential bias from an oversampling of 
those who purchase their asthma medications more frequently, crude weighting factors 
were devised based on the reported frequency of pharmacy visits. Estimates were 
made of the proportions of the population visiting pharmacies on various numbers of 
occasions in the previous year based upon the patient profile developed in a Drug 
Utilisation Survey. A sample of lllawarra pharmacists was asked to produce a patient 
profile for the previous 12 months of a systematic sample of 15 clients who obtained 
(B-agonist medication by prescription on at least one occasion. Data were obtained for 
284 patients and included the names, doses, quantities and dates of all medications 
obtained on prescription. Only partial information on age was obtained. Two different 
weighting factors were devised. The first was based on self reported frequency of 
pharmacy visits to obtain anti-asthma medication and the second on frequency of 
pharmacy visits to have prescriptions filled for p-agonist drugs. The weighting factors 
were calculated by dividing the population distribution by the sample distributions. 
These weighting systems were used for both the group mainly obtaining their P-agonist 
inhalers over the counter and those mainly using a prescription. Due to only 35 per cent 
of Drug Utilisation Survey patient profiles containing information on age, some are 
likely to be for those aged less than 15 years. The Pharmacy Exit Survey was only for 
those aged 15 years and over. 
The following classifications were used for anti-asthma drugs in this study. This 
classification is presented in full in the Pharmacists Asthma Management Handbook.̂ ® 
The first group of dnjgs are reliever medications (brand names for the drugs are shown 
in italics). The primary reliever drugs used are p-agonists which come in both short-
acting [eg. salbutamol {Asmol, Respolin, Ventolin); terbutaiine {Bhcanyl)\ fenoterol 
hydrobromide (Berotec)] and long-acting [eg. salmeterol {Serevent)] forms. The second 
group of reliever drugs are theophyllines [eg. Austyn, Elixophyllin, Nuelin, Slo-Bid, 
Theo-Dui] which are now considered to have limited importance in the treatment of 
asthma. The final reliever drug is ipratropium bromide [Atrovenf\ which is an anti-
cholinergic bronchodilator. 
The second classification of drugs are preventive medications. Sodium cromoglycate 
llntal\ is the first of this drug classification. Sodium cromoglycate inhibits the release 
of mediators of the allergic reaction from sensitised cells, preventing both the 
immediate and late asthmatic responses to stimuli. The second preventive medicator 
is Nedocromil sodium ITilade] which is mainly used in adults and children over 12 years 
of age. The third group of drugs in this classification are Inhaled Corticosteroids [eg. 
beclomethasone [Aldecin, Becioforte, Becotide]\ budesonide [Pulmicoi1\\ fluticasone 
[flixotide]. This group of drugs is the main preventive therapy for adults. Nebulised 
Corticosteroids are also available eg. budesonide [Pulmicoi1\ however their use is 
limited. The final group of preventive medications are oral corticosteroids eg. 
prednisolone and prednisone which are considered the most effective emergency 
medication for an acute asthma attack not responding to p-agonist. 
5. RESULTS 
5.1 1995 Pharmacy Exit Survey 
Six hundred and eighty three purchasers of anti-asthma medications aged 15 years and 
over were asked to fill in the one page written questionnaire. Of these 507 agreed 
giving a response rate of 74.2 per cent. Eighteen respondents reported chronic sputum 
production (at least 3 months continually) without being diagnosed with asthma and 
were excluded from further analysis. A comparison between respondents and non-
respondents of the written questionnaire is presented in Table 1. 
The median age of the respondents was 40 years with 47.9 per cent being male 
compared with 36 years and 53.8 per cent respectively for non-respondents. Ninety 
per cent of respondents reported having been diagnosed with asthma by a doctor 
compared with 86 per cent of non-respondents. Forty three per cent of respondents 
and 40.5 per cent of non-respondents reported chronic sputum production. The 
proportion of non-respondents obtaining their p-agonist inhalers over the counter on 
this occasion was 55.6 per cent compared with 40.2 per cent of respondents. Of the 
respondents 20.5 per cent reported that they always, and a further 14.9 per cent 
reported that they usually obtained their p-agonist medications over the counter, while 
51.1 per cent indicated that they always and 13.5 per cent usually used a prescription 
to obtain their 3-agonist medication. 
The respondents were more likely to have had their asthma diagnosed by a doctor (OR 
= 2.09, P = 0.022) and less likely to have obtained their anti-asthma medication over 
the counter on this occasion (OR = 0.54, P = 0.00082). There was no significant 
difference (using t-test) between the respondents and non-respondents in age (P = 
0.055), the proportion of males (OR = 0.79, P = 0.186), nor the proportion who reported 
chronic cough and sputum (OR = 0.93, P = 0.741). 






age (years)* 43.6 (40) 
n = 491 
42.6 (36) 
n = 174 
- 0.055 
sex (M) 47.9% 
n = 472 
53.8% 
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n = 378 
55.6% 




in parentheses. Difference tested using a t-
test. 
Respondents were classified as either mainly obtaining their anti-asthmatic medications 
over the counter or by prescription based upon their self reported frequency of using 
a doctors prescription to obtain p-agonist inhalers. Of the respondents 35.4 per cent 
reported never (20.5 per cent) or mostly not (14.9 per cent) using a prescription to 
obtain inhalers. These respondents were classified as mainly obtaining inhalers over 
the counter. Of the respondents 64.6 per cent reported mostly (13.5 per cent) or 
always (51.1 per cent) using a prescription to obtain inhalers and were hence 
categorised as mainly obtaining their inhalers by prescription. 
A comparison of those respondents predominantly obtaining their p-agonist inhalers 
over the counter and those using a prescription is shown in Table 2. The median age 
of the OTC group was 31 years compared with 50 years for the prescription group. The 
age difference was highly significant (P = 0.001). The OTC group (56.6 per cent) was 
more predominantly male (OR = 1.74, P = 0.004) than the prescription group (42.8 per 
cent). Of the prescription group, 48.1 per cent reported chronic cough and sputum 
compared with 32.5 per cent of the OTC group. There was no difference found in the 
proportion having asthma diagnosed by the doctor (OR = 0.98, P = 0.956). 
Table 2: Comparison of 'OTC group' and 'Prescription group' 





age (years)* 34.0 (31) 48.5 (50) - 0.001 
n = 171 n = 312 
sex (M) 56.6% 42.8% 1.74 0.004 
n = 168 n = 297 (1.17-2.60) 
asthma diagnosis 93.7% 93.8% 0.98 0.956 
by doctor n = 142 n = 242 (0.39-2.49) 
chronic cough and 32.5% 48.1% 0.52 0.006 
sputum n = 120 n = 210 (0.32-0.85) 
* Mean ages reported with median ages in parentheses. Difference tested using a t-
test. 
Table 3 shows indicators of disease severity compared between the OTC group and 
the prescription group. 
Of the respondents 69.6 percent reported at least daily use of their p-agonist inhalers 
and 18.1 per cent at least five times daily use, 60.6 per cent reported wheezing at least 
most days and 28.5 per cent every day, 51.0 per cent reported at least five attacks 
within the previous twelve months and 36.5 per cent reported at least ten attacks. Of 
the respondents 55.0 percent had been admitted to hospital with 'asthma' or 'wheeze' 
at least once previously and 13.7 per cent were admitted within the previous year. 
Table 3: Potential measures of disease severity compared between the 'OTC 
group' and the 'Prescription group' 
OTC Prescription Crude odds Adjusted P 
group group ratio odds ratio value 
(95% CI) (95% CI) 
wheeze at least 69.5% 80.9% 0.54 0.59 0.0320 
once per week n = 167 n = 303 (0.34-0.85) (0.39-0.96) 
wheeze most or 49.1% 67.0% 0.48 0.55 0.0052 
every day n = 167 n = 303 (0.32-0.71) (0.36-0.84) 
wheeze every day 20.4% 33.0% 0.52 0.66 0.0945 
n = 167 n = 303 (0.32-0.83) (0.40-1.07) 
at least 5 attacks 39.2% 57.6% 0.47 0.54 0.0039 
in the last year n = 171 n = 309 (0.32-0.71) (0.35-0.80) 
at least 10 attacks 25.7% 42.4% 0.47 0.51 0.0035 
last year n = 171 n = 309 (0.31-0.72) (0.33-0.80) 
hospital admission 54.8% 55.1% 0.99 0.79 0.2746 
ever for asthma or n = 168 n = 305 (0.66-1.47) (0.52-1.20) 
wheeze 
hospital admission 7.14% 17.4% 0.37 0.31 0.0009 
within the last 12 n = 168 n = 305 (0.18-0.73) (0.16-0.62) 
months 
use of beta- 61.4% 74.1% 0.56 0.64 0.0451 
agonist puffer at n = 175 n = 309 (0.37-0.85) (0.42-0.99) 
least daily 
use of beta- 15.2% 19.7% 0.73 0.79 0.4122 
agonist puffer at n = 168 n = 305 (0.43-1.24) (0.46-1.38) 
least 5 times daily 
more than 25 8.24% 20.9% 0.34 0.42 0.0112 
visits to pharmacy n = 170 n = 307 (0.18-0.65) (0.21-0.82) 
for medication 
These potential measures of disease severity were compared between the two groups. 
In the crude analysis and after adjusting for age and sex the OTC group was less likely 
to report wheezing at least once per week (OR = 0.59; 95% CI = 0.39-0.96; P = 0.0320) 
as well as at least most days (OR = 0.55; 95% CI = 0.36-0.84; P = 0.0052). In the 
crude analysis, the OTC group was less likely to report wheezing every day (OR = 0.52, 
P = 0.004) however after adjusting for differences in age and sex, this difference was 
not significant (OR = 0.66, 95% CI = 0.40-1.07; P = 0.0945). 
The prescription group was more likely to have had at least 5 attacks in the last year 
(OR = 0.54, 95% CI = 0.35-0.80, P = 0.0039) and to have had at least 10 attacks last 
year (OR = 0.51, 95% CI = 0.33-0.80, P = 0.0035). The prescription group was also 
more likely to have been admitted to hospital within the last 12 months for asthma or 
wheeze (OR = 0.31, 95% CI = 0.16-0.62, P = 0.0009), to use their (3-agonist puffer at 
least daily (OR = 0.64, 95% CI = 0.42-0.99, P = 0.0451), and to make more than 25 
visits to the pharmacy in the last 12 months to obtain medication (OR = 0.42, 95% CI 
= 0.21-0.82, P = 0.0112). There were no significant differences found in the proportion 
of people who had ever been admitted to hospital for asthma or wheeze (OR = 0.79, 
P = 0.2746) or in those reporting use of P-agonist puffers at least 5 times daily (OR = 
0.79 P = 0.4122). 
Table 4 shows weighted and crude prevalence estimates of factors related to the 
management of adult asthma compared between the OTC group and the prescription 
group. The weighted estimates are based upon self reported frequency of pharmacy 
visits to obtain anti-asthma medication. The table is also shown in appendix 5 with 
weighted estimates based upon frequency of pharmacy visits to have prescriptions 
filled for P-agonist drugs. Minimal changes were noted in the prevalence estimates of 
the management factors as a result of this methodology. 
Table 4: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 'OTC group' and the 
'Prescription group' 
Total OTC Prescription Crude Adjusted P 
population group group odds ratio odds ratio value 
(95% CI) (95% CI) 
objective airways 27.9% 25.4% 32.2% 0.56 0.37 0.0011 
measurement by the (31.1%) (23.4%) (35.4%) (0.36- (0.21-
doctor 'usually' or n = 171 n = 308 0.87) 0.67) 
'always' 
peak flow readings 28.1% 26.2% 27.8% 0.69 0.67 0.1597 
at home (31.0%) (25.7%) (34.0%) (0.45- (0.38-
n = 171 n = 306 1.08) 1.17) 
instruction in inhaler 92.8% 92.8% 93.3% 0.69 0.87 0.7407 
technique (93.4%) (91.8%) (94.2%) (0.32- (0.37-
n = 171 n = 311 1.51) 2.01) 
written action plan 24.7% 20.5% 27.6% 0.55 0.48 0.0184 
(27.8%) (20.5%) (31.8%) (0.35- (0.26-
n = 171 n = 311 0.88) 0.88) 
regular medical 53.7% 45.3% 60.7% 0.31 0.50 0.0297 
review at least once (60.2%) (42.2%) (70.3%) (0.19- (0.27-
per year n = 135 n = 239 0.49) 0.93) 
regular medical 40.3% 33.6% 47.9% 0.25 0.32 0.0009 
review at least twice (48.4%) (27.4%) (60.3%) (0.15- (0.17-
per year n = 135 n = 239 0.40) 0.64) 
As recommended management depends on disease severity, the crude estimates of 
the difference between the OTC and prescription groups were adjusted for the potential 
measures of disease severity along with age and sex. 
Of the total population, 27.0 per cent (21.7 per cent of the OTC group and 29.8 per cent 
of the prescription group) did their own peak flow readings at home. Of the 
respondents 24.9 per cent (18.9 per cent of the OTC group and 28.7 per cent of the 
prescription group) had a written action plan. Of the respondents 53.9 per cent (43.2 
per cent of the OTC group and 61.1 per cent of the prescription group) reported having 
regular medical review at least once per year. Of the respondents 39.7 per cent (25.2 
per cent of the OTC group and 48.4 per cent of the prescription group) had regular 
medical review at least twice per year. After adjusting for potential measures of 
disease severity, age, and sex, there were significant differences between the OTC 
group and the prescription group in regards to; objective airways measurement by the 
doctor 'usually' or 'always' (OR = 0.37; 95% CI = 0.21-0.67; P = 0.0011), possession 
of a written action plan (OR = 0.48; 95% CI = 0.26-0.88; P = 0.0184), regular medical 
review at least once per year (OR = 0.50; 95% CI = 0.27-0.93; P = 0.0297), and regular 
medical review at least twice per year (OR = 0.32; 95% CI = 0.17-0.64; P = 0.0009). 
The proportion of adult asthmatics who use various medications regulariy ('most of the 
time') are presented in Table 5, with the use of medications at any time (those 
indicating taking medications 'most of the time' and 'in bad attacks') in the previous six 
months presented in Table 6. Again the weighted estimates are based upon the 
frequency of pharmacy visits to obtain anti-asthma medication. The results of using 
frequency of pharmacy visits to have prescriptions filled for p-agonist drugs as the 
basis for the weighting factors are presented in appendix 5. Again only minor 
differences were noted between the two weighted estimates. 
Table 5: Weighted (and crude) prevalence estimates of the use medications 
regularly during the previous six months compared between the 'OTC group' 
and the 'Prescription group' 
Total 
population 
n = 483 
OTC 
group 
n = 171 
Prescription 
group 













































































































It is estimated that 55.0 per cent of adult asthmatics (43.4 per cent of the OTC group 
and 61.6 per cent of the prescription group) regularly used inhaled preventative 
medications (corticosteroids or sodium cromoglycate), and 35.1 per cent have used 
antibiotics and 15.3 percent have used antihistamines 'for chest problems' within the 
previous six months. 
After adjusting for age, sex, and indicators of disease severity the OTC group is less 
likely to regularly use inhaled preventative medications (OR = 0.29; 95% CI = 0.16-
0.51; P = 0.0001), inhaled corticosteroids (OR = 0.35; 95% CI = 0.20-0.60; P = 0.0001), 
ipratropium (OR = 0.27; 95% CI = 0.09-0.88; P = 0.0289) and theophylline (OR = 0.30; 
95% CI = 0.11 -0.79; P = 0.0151). The OTC group is less likely to have used inhaled 
corticosteroids (OR = 0.35; 95% CI = 0.21-0.61; P = 0.0002), ipratropium (OR = 0.44; 
95% CI = 0.20-0.94; P = 0.0480) and theophylline (OR = 0.43; 95% CI = 0.20-0.94, P 
= 0.0348) for chest problems at any time within the previous six months. 
Table 6: Weighted (and crude) prevalence estimates of use of medications at 
any time during the previous six months compared between the 'OTC group' 
and the 'Prescription group' 
Total 
population 
n = 477 
OTC 
group 
n = 171 
Prescription 
group 











































































































Due to slight changes in methods of data analysis for the 1995 sample to those 
previously reported®®, the results of an identical analysis of the 1991 data are reported 
in appendix 4. 
5.2 Changes between 1991 and 1995 
A comparison between 1991 and 1995 respondents is shown in Table 7 below. There 
were no statistically significant differences found between the 1991 and 1995 groups 
of respondents in regards to age, sex, asthma diagnosis by doctor, and chronic cough 
and sputum. The median age for both 1991 and 1995 respondents was 40 years. The 
proportion of those respondents who were male decreased between 1991 and 1995 
(53.3 per cent in 1991 to 47.9 per cent in 1995) however this difference was not 
statistically significant (OR = 1.24, P = 0.105). The number of respondents that 
reported having their asthma diagnosed by a doctor decreased slightly (95.4 per cent 
in 1991 to 93.5 per cent in 1995) as did the proportion reporting chronic cough and 
sputum (46.2 percent in 1991 to 43.0 percent in 1995) however neither change was 
statistically significant. 
Table 7: Comparison of 1991 and 1995 respondents 
1991 1995 Odds ratio 
(95% CI) 
P value 
age (years)* 42.1 (40) 
n = 419 
43.4 (40) 
n = 478 
- 0.055 





95.4% 93.6% 1.41 
(0.70-2.87) 
0.303 
chronic cough and 
sputum 
46.2% 43.0% 1.14 
(0.80-1.61) 
0.443 
* Mean ages reported with median ages in parentheses. Difference tested using a t-
test. 
There has been a slight but insignificant increase in the proportion of respondents 
using a prescription to obtain p-agonist inhalers from 61.2 per cent in 1991 to 64.6 per 
cent in 1995 (OR = 1.16, P = 0.243). The self reported frequency of use of a 
prescription to obtain p-agonist inhalers is shown in Table 8. 
Table 8: Self reported frequency of prescription use to obtain p-agonist 
inhalers compared between 1991 and 1995 respondents. 
Use of Prescription 1991 1995 
n=:423 n = 483 
Never 23.9% 20.5% 
Mostly Not 14.9% 14.9% 
"Over the counter group" 38.8% 35.4% 
Mostly 13.2% 13.5% 
Always 48.0% 51.1% 
"Prescription group" 61.2% 64.6% 
Potential measures of disease severity compared between 1991 and 1995 are shown 
in table 9. Slight reductions from 1991 to 1995 were found in the proportion reporting; 
wheeze at least once per week, wheeze most or every day, wheeze every day, at least 
five attacks of asthma or wheezing last year, at least 10 attacks of asthma or wheezing 
last year, hospital admission for asthma or wheezing within the last 12 months and the 
use of p-agonist puffers at least daily. In the crude analysis however, none of these 
potential disease severity measures had changed significantly. After adjusting for age 
and sex, the reduction in the use of p-agonist puffers at least daily from 75.3 per cent 
in 1991 to 69.6 percent in 1995 was of marginal significance (OR = 1.08; 95% CI = 
1.00-1.16; P = 0.0500). 
Table 9: Potential measures of disease severity compared between 1991 and 
1995 respondents 








wheeze at least 
once per week 
78.5% 
n = 405 
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wheeze most or 
every day 
63.5% 
n = 405 
60.8% 






wheeze every day 29.6% 
n = 405 
28.9% 
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in the last year 
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in the last year 
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ever for asthma or 
wheeze 
50.5% 
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54.7% 







within the last 12 
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14.9% 
n = 424 
14.1% 







agonist puffer at 
least once a week 
93.8% 
n = 417 
90.7% 







agonist puffer at 
least a few times a 
week 
92.1% 
n = 417 
86.0% 







agonist puffer at 
least daily 
75.3% 
n = 417 
69.6% 







agonist puffer at 
least 5 times daily 
15.4% 
n = 417 
18.3% 








more than 10 
times a day 
3.84% 
n = 471 
3.29 






Various management factors were compared between 1991 and 1995 as shown in 
Table 10 below. Weighted estimates are based on self reported frequency of 
pharmacy visits to obtain anti-asthma medications. The prevalence of reporting; peak 
flow readings at home increased from 19.5 percent in 1991 to 27.0 percent in 1995 
(OR = 0.71, P = 0.022) and the prevalence of reporting regular medical review at least 
once per year also increased, from 46.5 per cent in 1991 to 53.9 per cent in 1995 (OR 
= 0.71, P = 0.024). After adjusting for potential measures of disease seventy, age and 
sex, the differences were not statistically significant for both peak flow readings at 
home (OR = 0.94; 95% CI = 0.86-1.03; P = 0.2060) and regular medical review at least 
once per year (OR = 0.92; 95% CI = 0.83-1.02; P = 0.1127) or for any of the other non-
medication related management factors. 
Table 10: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 1991 and 1995 
respondents 









measurements by the 




n = 422 
28.4% 
(31.4%) 










n = 421 
27.0% 
(31.3%) 










n = 421 
90.9% 
(93.1%) 






written action plan 18.4% 
(22.8%) 
n = 417 
24.9% 
(27.6%) 






regular medical review 
at least once per year 
46.5% 
(51.6%) 
n = 314 
53.9% 
(60.2%) 






regular medical review 
at least twice per year 
36.2% 
(43.3%) 
n = 314 
39.7% 
(48.6%) 






A Gomparison between 1991 and 1995 of the regular use of various medications is 
shown in Table 11, with use at any time shown in Table 12. Again weighted estimates 
are based on frequency of pharmacy visits for anti-asthma medications. The proportion 
of respondents using inhaled corticosteroids increased from 39.3 percent in 1991 to 
48.0 per cent in 1995 (OR = 0.90, 95% CI = 0.83-0.98, P = 0.016) and use of sodium 
cromoglycate has increased from 9.12 per cent to 13.4 per cent in 1995 (OR = 0.82, 
95% CI = 0.73-0.93, P = 0.0015). The proportion of respondents reporting use of 
theophyllines decreased from 19.0 per cent in 1991 to 9.58 per cent in 1995 (OR = 
1.27, 95% CI = 1.14-1.41, P = 0.0001). 
Table 11: Weighted (and crude) prevalence estimates of the use of 
medications regularly during the previous six months compared between 1991 
and 1995 respondents 
1991 1995 Crude odds Adjusted P value 
n = 421 n = 491 ratio odds ratio 
(95% CI) (95% CI) 
inhaled 43.7% 55.0% 0.64 0.87 0.0019 
corticosteroids or (51.1%) (62.1%) (0.48-0.83) (0.80-0.95) 
cromoglycate 
inhaled 39.3% 48.0% 0.73 0.90 0.0160 
corticosteroids (46.4%) (54.4%) (0.55-0.95) (0.83-0.98) 
cromoglycate 9.12% 13.4% 0.58 0.82 0.0015 
(10.5%) (16.7%) (0.39-0.88) (0.73-0.93) 
ipratropium 9.14% 10.7% 0.77 0.91 0.1542 
(14.0%) (17.5%) (0.53-1.11) (0.81-1.03) 
theophylline 19.0% 9.58% 2.13 1.27 0.0001 
(24.2%) (13.0%) (1.49-3.05) (1.14-1.41) 
oral 6.00% 5.81% 0.95 0.98 0.7894 
corticosteroids (8.39%) (8.76%) (0.59-1.55) (0.86-1.13) 
antibiotics 16.0% 15.3% 0.92 1.01 0.8277 
(15.2%) (16.3%) (0.63-1.33) (0.91-1.13) 
No significant changes were found in the regular use or the use at any time of 
ipratropium, oral corticosteroids, antihistamines and antibiotics in the previous six 
months. 
Table 12: Weighted (and crude) prevalence estimates of the use of 
medications at any time (regularly and/or during bad attacks) compared 
between 1991 and 1995 respondents 
1991 
n = 421 
1995 









inhaled 47.0% 55.4% 0.80 0.94 0.1392 
corticosteroids (54.6%) (60.1%) (0.61-1.05) (0.86-1.02) 
cromoglycate 11.2% 13.5% 0.68 0.87 0.0117 
(13.5%) (18.7%) (0.47-0.98) (0.77-0.97) 
ipratropium 13.9% 15.5% 0.85 0.95 0.3901 
(20.3%) (23.0%) (0.61-1.18) (0.86-1.06) 
theophylline 25.8% 13.5% 2.10 1.27 0.0001 
(32.6%) (18.7%) (1.53-2.88) (1.15-1.40) 
oral 15.4% 18.4% 0.87 0.99 0.8559 
corticosteroids (21.7%) (24.2%) (0.63-1.19) (0.90-1.09) 
antihistamines 12.9% 15.3% 0.78 0.93 0.2012 
(13.5%) (16.7%) (0.53-1.14) (0.83-1.04) 
antibiotics 35.0% 35.1% 0.91 0.99 0.7975 
(36.8%) (39.1%) (0.69-1.20) (0.91-1.07) 
6. STUDY LIMITATIONS 
The repeated cross-sectional study design is limited in that there are no control areas 
to determine whether local or national Initiatives have had any affect. The study cannot 
be generalised to an area outside of the lllawarra region of New South Wales. 
Although there was an attempt to exclude those with chronic bronchitis in the Pharmacy 
Exit Survey, there may still be some in the study population of both the Drug Utilisation 
Survey and the Pharmacy Exit Survey. The criteria which was used to exclude people 
with chronic bronchitis should keep the numbers small. It is possible that those people 
with very mild asthma would not make it into the sample due to their infrequent need 
to visit a pharmacy. Some mild asthmatics may not actually be using drug therapy and 
hence not visit a pharmacy at all. 
Although prevalence estimates of management indicators were weighted in an attempt 
to adjust for the fact that more severe asthmatics would visit community pharmacies 
more frequently, it is possible that disease severity has still not been adequately 
adjusted for. 
Although pharmacists were specifically requested to approach consecutive clients in 
the Pharmacy Exit Survey, there was no means of assuring this. It is possible that 
pharmacists may not have actually recorded all non-responders which would increase 
the response rate. Where there was more than one pharmacist working at a particular 
pharmacy, it is not known whether consecutive clients were approached by just one 
pharmacist or by all pharmacists at the pharmacy. This may be relevant where certain 
pharmacists may work set shifts which may service customers with different 
characteristics. It is also not known whether just pharmacists or pharmacy assistants 
were involved in administering the survey. 
Although a reliability check was made on the questionnaire in 1991, the questionnaire 
has not been validated, except for the initial questions relating to asthma diagnosis and 
chronic cough and sputum which were recorded on the pharmacists data sheet. 
None of the measures of disease severity used in the Pharmacy Exit Survey were 
objective and ail were self-reported. The measurement of whether respondents have 
asthma, although previously validated is still a subjective measure. 
Although most questions from the Pharmacy Exit Survey questionnaire had a very high 
rate of completeness, the question relating to respondents visiting the doctor about 
their chest were not answered by as many respondents as the rest of the questionnaire. 
The questionnaire was also affected by some minor wording changes in 1995. These 
changes are not expected to significantly alter the respondents interpretation of those 
questions affected. 
The Dmg Utilisation Survey also possibly suffers selection bias due to the non-random 
selection of pharmacies to be involved in the study. The work involved in providing the 
information from the pharmacy databases is extensive and very time consuming and 
hence only those pharmacists who were interested in asthma were asked to participate. 
Another issue in the Drug Utilisation Survey is the extent of passing trade which was 
received by pharmacies. In 1995, the participating pharmacies were considered to be 
affected little by passing trade. The smaller the amount of passing trade, the higher the 
quality of information relating to asthma sufferers prescribed medication use. 
There are a number of deficiencies with the methodology used to control for the likely 
oversampling of more severe asthmatics visiting community pharmacies more 
frequently to obtain anti-asthma medications. Firstly the data collected in the Drug 
Utilisation Survey is limited to prescribed anti-asthma medications and does not include 
those customers purchasing beta-agonist inhalers over the counter. The corresponding 
question in the Pharmacy Exit Survey which was used both in 1991 and 1995 refers to 
pharmacy visits to obtain medication for the chest. In 1995 the more appropriate 
question 13 was added to the Pharmacy Exit Survey which referred specifically to 
pharmacy visits to have prescriptions filled for beta-agonist drugs. In order to compare 
between 1991 and 1995, the first less appropriate question had to be used to weight 
the prevalence estimates of management factors. Nevertheless, as discussed in the 
results, it is reassuring that the estimate did not differ appreciably depending on which 
question was used to derive the weighting factor for the 1995 data. 
Secondly, the data able to be obtained on age from the Drug Utilisation Survey was 
limited and hence some of those aged less than 15 years are included in the sample. 
In the Pharmacy Exit Survey, pharmacists were instructed to only administer the 
questionnaire to customers who were 15 years of age and over. Some aged less than 
15 years were surveyed, however more complete data on age allowed their exclusion 
from the sample. Therefore the two sample populations differ in that the Pharmacy Exit 
Survey includes those purchasing beta-agonist inhalers over the counter whereas the 
Drug Utilisation Survey only includes data on prescriptions, and the Drug Utilisation 
Survey possibly includes some individuals aged less than 15 years. 
Because only people obtaining their medication by prescription were sampled in the 
Dnjg Utilisation Survey, mild asthmatics would have been under-represented in these 
data. This is another reason why it is likely that the prevalence estimate of 
management factors have not adequately adjusted for the over-representation of more 
severe asthmatics. 
7. DISCUSSION 
The group predominantly obtaining their P-agonists over the counter is younger, more 
likely to be male, and less likely to report chronic cough and sputum. Males are less 
likely to go to the doctor than females®\ and hence less likely to obtain a script. There 
are quite large financial benefits from obtaining various anti-asthma medications on 
prescription rather than over the counter for those people holding a concession card. 
P-agonists can be obtained for around a quarter of the price if a script and concession 
card is used. Holders of concession cards are generally older and hence use a script 
in order to obtain the financial benefits. Older people are also more likely to visit a 
general practitioner for problems other than asthma and may obtain scripts for anti-
asthma medications on the same visit. 
Although there has only been a statistically insignificant increase in the proportion of 
respondents mainly obtaining their p-agonists by prescription, it is similar to the 
increase noted in a similar study in the Hunter Valley region of NSW in 1989.®^ It is 
unlikely that there would be an increase in the proportion using a prescription to obtain 
P-agonist inhalers without an increase in the proportion of people having routine 
medical review. 
In 1991, the only difference in potential disease severity indicators between the OTC 
group and the prescription group were in hospital admissions for asthma or wheeze. 
In 1995 the differences between the OTC group and the prescription group were more 
prominent with regards to disease severity with the prescription group more likely to 
wheeze at least once per week, wheeze most or every day, have at least 5 attacks of 
asthma or wheeze in the last year, have at least 10 attacks of asthma or wheeze in the 
last year, to be admitted to hospital within the last 12 months for asthma or wheeze and 
to use a p-agonist inhaler at least daily. These differences were evident both in the 
crude analysis and after adjusting for age and sex. This suggests that the gap between 
the OTC group and the prescription group with regards to disease severity may be 
widening. More severe cases of asthma are more likely to be prescribed preventative 
drugs which are only available by prescription and obtain their p-agonists prescriptions 
at the same time. 
As in 1991, in 1995 the OTC group was significantly less likely, both in crude and 
adjusted analysis, to have objective airways measurement by the doctor 'usually' or 
'always' (OR = 0.37; 95% CI = 0.21-0.667; P = 0.0011), regular medical review at least 
once per year (OR = 0.50; 95% CI = 0.27-0.93; P = 0.0297) and regular medical review 
at least twice per year (OR = 0.32; 95% CI = 0.17-0.64; P = 0.0009). In 1995 there was 
an additional difference between the OTC group and the prescription group in that the 
prescription group were more likely to have a written action plan of what to do in an 
attack (OR = 0.48; 95% CI = 0.26=0.88; P = 0.0184). This difference may also be 
related to improved management by general practitioners. The National Asthma 
Strategy Goals and Targets set by the National Asthma Campaign aimed for 21 per 
cent of people to have a written action plan by the year 2000. The baseline for this 
target is 14 per cent of adults with a written action plan.®^ A repeat of this survey in 
1993 found the proportion of people with a written action plan to be 19.9 per cent.^ 
Therefore it can be seen that the lllawarra in 1995 had a reasonably good proportion 
of adults with written action plans (24.9 per cent) and the magnitude of the 
improvement since 1991 was similar to the National Asthma Campaign survey 
completed slightly earlier. The National Asthma Campaign sampling method was very 
different from that of the lllawarra survey. The National Asthma Campaign survey 
sampled parents of a random sample of primary schoolchildren from Sydney, 
Melbourne, Brisbane and the Upper Hunter Valley (New South Wales). It is also 
possible that the weighting method used here in the lllawarra sample does not 
adequately adjust for the oversampling of people with more severe asthma. 
The proportion of the respondents reporting objective airways measurement by the 
doctor 'usually' or 'always' (28.4 per cent) and measurement of peak flow at home (27.0 
percent) were still low in 1995. The National Asthma Campaign survey reported that 
in 1993, 29.9 per cent of adult asthmatics had a peak flow meter and 44.4 per cent had 
their lung function measured by the doctor in the previous year. 
There has been considerable debate recently as to whether frequency of p-agonist 
medication use is an indication of disease severity or of management. Logistic 
regression analysis was run without including frequency of [B-agonist use as a potential 
confounder in analyses related to asthma management. The results are presented in 
appendix 6. Minimal changes were observed in the odds ratio estimates for the 
management indicators, and therefore the use of P-agonists is not considered to be a 
significant confounder of asthma management here. 
In 1991 there was a significant difference between the OTC group and the prescription 
group in the reported regular use of oral corticosteroids, however in 1995, this 
difference was not evident. The opposite is the case with the use of theophylline which 
showed no significant difference between the OTC group and the prescription group 
in 1991, however in 1995 the difference is significant at the 0.05 level (OR = 0.30; 95% 
CI = 0.11-0.79; P = 0.0151). This difference was also noted in the use of theophylline 
at any time (OR = 0.43; 95% CI = 0.20-0.94; P = 0.0348). This is a positive result as 
the Asthma Management Plan recommends close supervision of the use of 
theophylline.^ Overall, regular theophylline use decreased from 19.0 percent to 9.6 
per cent. This reduction in the use of theophyllines is not as great as that seen in the 
second evaluation survey done for the National Asthma Campaign. They report a 
significant reduction in theophylline use from 20.5 percent in 1990 to 3.9 percent in 
1993.®® Again it is possible that the weighting method used in the lllawarra survey has 
not adequately adjusted for an oversampling of people with more severe disease. 
Differences were found in regular use of inhaled corticosteroids and ipratropium 
between the 'over the counter' group and the prescription group both in 1991 and 1995. 
While there were slight improvements in most indicators of disease severity between 
1991 and 1995, these changes were not significant except in relation to the frequency 
of use of p-agonist inhalers. Reductions in the proportion of people using p-agonist 
inhalers between at least a few times a week and at least daily suggest improved 
disease severity and/or asthma management. Changes in prescribing which have 
been made are in accordance with the Asthma Management Plan with increased 
prescribing of inhaled corticosteroids and a reduction in the reliance on regular use of 
P-agonist inhalers. These changes have occurred in those people who have a 
moderate (between a few times a week and four times a day) usage of (3-agonist 
inhalers rather than those with a very high (more than 5 times a day) usage of P-agonist 
inhalers. 
While most non-medication related management indicators improved slightly between 
1991 and 1995, these changes were not significant. This is possibly due to a lack of 
statistical power and/or that the emphasis of the asthma management plan and local 
initiatives has been on better prescribing. The proportion of people having regular 
medical review even when their chest is not causing problems is probably higher than 
previously thought. Westley-Wise et al reported 38.1 per cent of those responding to 
the 1991 pharmacy exit survey having regular medical review at least once per year, 
and 32.1 per cent at least twice per year.®^ The corresponding proportions for the 
reanalysis of the 1991 pharmacy exit survey were 51.6 per cent and 43.3 per cent 
which are significantly higher. The initial analysis by Westley-Wise ei a/assumed 
non-respondents to this question did not have regular medical review. Results of the 
1991 reanalysis are presented in full in appendix 4. 
There has undoubtedly been an improvement in the prescribing of anti-asthma drugs 
in the lllawarra between 1991 and 1995. Significant improvements in the regular use 
of either inhaled corticosteroids or cromoglycate and a dramatic decrease in use of 
theophylline indicates changes in prescribing in line with the recommendations of the 
asthma management plan. The changes in preventative maintenance therapy have not 
been as great as those put forward in the National Asthma Campaign goals and targets 
document. The target is for 80 per cent of the adult asthmatic population to use 
preventative maintenance therapy by 1996, based upon a baseline measure of 39 per 
cent in 1990.^ The National Asthma Campaign survey reported 38 per cent using 
inhaled corticosteroids or sodium cromoglycate in 1990. This increased to 43 per cent 
by 1993.®® The increase in the lllawarra from 44 percent in 1991 to 55 per cent in 1995 
suggests a higher baseline and a greater increase in the lllawarra, however this may 
reflect the different surveillance methods used for the national and lllawarra estimates. 
This increase was significant after adjusting for age, sex and potential measures of 
disease severity (OR = 0.87; 95% CI = 0.80-0.95; P = 0.0019). 
8. CONCLUSIONS AND RECOMMENDATIONS 
Prescribing changes are evident through increases in the proportion of respondents 
who are using preventative medications and a decrease in the use of theophyllines. 
These change are in line with those recommended by the asthma management plan. 
Changes in non-dmg related asthma management factors were minor. This is possibly 
due to the emphasis which has been placed on improved drug management, or the 
failure of non-drug asthma management education to reach the target audience. There 
is some suggestion that that asthma severity may have improved slightly between 1991 
and 1995 which may be associated with an increase in use of preventative medications 
and a slight decline in frequent p-agonist use. 
The increased distinction in disease severity and asthma management indicators 
between the OTC group and the prescription group emphasises the importance of 
regular medical consultation and supervised asthma management. The problem of 
asthma sufferers not having regulair medical review should be adequately addressed 
through the recent introduction of the asthma card throughout the lllawarra. The 
asthma card aims to monitor unsupen/ised (3-agonist use and encourages users to have 
routine medical review of asthma. 
A coherent strategy involving as many lllawarra general practitioners and pharmacists 
as possible is recommended. Improved asthma management should be promoted with 
an emphasis on non-pharmacological issues such as the use of written action plans, 
peak expiratory flow measurement, and regular medical review. Previous local 
initiatives have only involved a small sample of interested lllawarra general 
practitioners. A concentrated local program with the above aims is needed to 
complement the strategies of the National Asthma Campaign. 
The usefulness of the Pharmacy Exit Survey and the Drug Utilisation Survey is shown 
in this study and in order to evaluate the introduction of the asthma card in the lllawarra 
and other strategies presently being prepared, these surveys should again be repeated 
in 1999. The use of pharmacies for sample recruitment has produced excellent results 
and should continue to be used to monitor adult asthma management in the lllawarra. 
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ABSTRACT 
Objective: To describe recent trends in adult asthma management and to compare 
between groups primarily obtaining p-agonist inhalers 'over the counter' (the OTC 
group) and by prescription (the prescription group). 
Setting: Consecutive clients of community pharmacies in the lllawarra purchasing anti-
asthmatic medications. 
Design: Repeated cross-sectional surveys of adults (aged 15 years and over) in 1991 
and 1995. Data from a second study of drug prescriptions dispensed by community 
pharmacies were used to determine prevalence estimates of various asthma 
management indicators for a population of adults with asthma. 
Results: P-agonist inhalers were primarily obtained over the counter by 35.4 per cent 
of respondents. The prescription group reported more severe disease than the OTC 
group. After taking into account differences between the two groups in disease 
severity, age and sex the OTC group was less likely to use either inhaled 
corticosteroids or sodium cromoglycate (OR=0.29, Cl=0.16-0.51), or ipratropium 
bromide (OR=0.27, CI=0.09-0.88) regularly during the previous six months, and less 
likely to have used inhaled corticosteroids (OR=0.15, Cl=0.21-0.61), and ipratropium 
bromide (OR=0.44, CI=0.20-0.94) at any time. The OTC group was also less likely to 
have routine medical review at least once per year (OR=0.50, CI=0.27-0.97), have their 
airways objectively measured by the doctor usually or always (OR=0.37, Cl=0.21 -0.67) 
and to have a written action plan (OR=0.48, CI=0.26-0.88). No significant improvement 
in non-drug related asthma management indicators between 1991 and 1995 was 
evident. However, prescribing patterns improved with increases in the regular use of 
inhaled corticosteroids or sodium cromoglycate and a reduction in the use of 
theophylline. It is estimated that 55.0 per cent of adults with asthma now use inhaled 
preventative medications regularly, 24.9 percent have written action plans, and 53.7 
per cent have routine medical review at least once per year. 
Conclusions: Improvements in asthma management are sub-optimal, particularly for 
people who primarily obtain their P-agonist inhalers over the counter. The recent 
introduction of the 'Asthma Card' in the lllawarra should address some of these issues. 
INTRQDUnTION 
The National Asthma Campaign (NAC) began in 1989 with the aim of improving the 
management of asthma through the promotion of a recognised 'Asthma Management 
Plan'.^ The Asthma Management Plan draws on evidence that many asthma deaths 
are associated with undertreatment related to an over-reliance on bronchodilator 
medication and underuse of inhaled and oral corticosteroids, failure to make objective 
measurement of disease severity and inadequate supervision.^-^ "̂'® ® Up to two thirds of 
all asthma deaths may be associated with preventable factors^ and with currently 
available medication, morbidity from asthma can be reduced.® The first phase of the 
NAC was aimed at health professionals, and included mail-outs and advertisements in 
frequently read medical journals promoting the asthma management plan.® The second 
and third phases of the campaign promoted increased awareness to the asthma 
sufferer and the general community respectively.^® 
In 1991 the lllawarra Pharmacists Association in conjunction with the lllawarra Area 
Health Service and the University of Wollongong Department of Mathematics undertook 
the a survey of adult asthma management amoung people obtaining their medication 
from community pharmacies in the lllawarra. This survey was repeated in 1995 
allowing evaluation of improvement in adult asthma management over this time period, 
as a result of both national and local initiatives. 
Respondents predominantly obtaining their medications by prescription in the 1991 
Pharmacy Exit Survey were managed better than those primarily purchasing their IB-
agonist inhalers over the counter, however the management of both groups was sub-
optimal.^^ Reported here are current levels of asthma management described in terms 
of the National Asthma Campaign recommendations. Those management indicators 
are compared between those predominantly obtaining their p-agonist inhalers by 
prescription and those primarily purchasing them over the counter as well as analysing 
changes between 1991 and 1995. Crude prevalence estimates of asthma management 
factors were weighted using data from another study of asthma drug prescriptions in 
an attempt to adjust for the potential bias from an oversampling of those who purchase 
their medications more frequently. . 
METHODS 
The same survey methodology was used in 1995 as in 1991, except for slight changes 
to the questionnaire, and small differences in the methods of analysis from the original 
study.""^ All pharmacies (66) in the lllawarra area were asked to participatein both 1991 
and 1995. Each pharmacist was asked to recruit 12 consecutive clients aged 15 years 
or over obtaining any anti-asthmatic medications (3-agonists, theophyllines, inhaled 
corticosteroids, ipratropium, or sodium cromoglycate) to fill in the one page 
questionnaire. Each pharmacist completed a data sheet including: the gender and age 
(estimated for non-responders); their answers to two questions derived from a 
previously validated questionnaire^^ (concerned with previous asthma diagnosis and 
chronic sputum production); and whether they agreed or refused to complete the 
questionnaire. The questions concerned with sputum production and asthma diagnosis 
were used to exclude people with chronic bronchitis (defined as reporting chronic 
sputum production and never been diagnosed with asthma) at the data analysis stage. 
The questionnaires include questions related to asthma management practices such 
as use of peak flow meters, written plans, medication, and medical supervision. Also 
included were questions related to asthma severity such as frequency of wheezing and 
"attacks" of asthma and wheeze, previous hospitalisation, and frequency (3-agonist 
inhaler use. In addition two questions concerned the frequency of visits to community 
pharmacies to obtain anti-asthma medications and to have scripts filled for p-agonists. 
The data were entered into Epilnfo v5.1 and analysed using SAS v6.10 for Windows. 
Prevalence estimates were made of indicators related to asthma severity and asthma 
management. Crude odds ratios were used to compare severity and asthma 
management indicators between groups who reported mainly obtaining p-agonists over 
the counter or mainly by prescription in 1995 and between the 1991 and 1995 groups. 
Statistical significance was established by means of the chisquared test. Confidence 
limits of the crude odds ratios were calculated by the methods of Cornfield using 
Epilnfo v6.0. 
The crude odds ratios for potential measures of disease severity were adjusted for age 
and sex by logistic regression analysis. The crude odds ratios for asthma management 
factors were adjusted for age, sex and indicators of disease severity using stepwise 
logistic regression analysis. Indicators of disease severity were frequency of wheezing 
(categorised as at least weekly, at least most days, and at least daily), frequency of 
asthma attacks (categorised as at least five and at least 10 in the last year), frequency 
of pharmacy visits to obtain "chest" medication (categorised as at least once in the last 
12 months, at least 3-4 times, at least 5-10 times, at least 11-25 times and more than 
25 times), previous hospitalisation (characterised as ever and within the last year), and 
frequency of inhaler use (characterised as at least once a week, a few times per week, 
once a day, five times a day, and more than ten times a day). The logistic regression 
analysis were also run without including frequency of inhaler use as a potential 
confounder, however the results were essentially unchanged. Statistical significance 
will be shown at the 0.05 level with 95 per cent confidence limits. 
In order to adjust prevalence estimates of asthma management factors for the potential 
bias from an oversampling of those who purchase their asthma medications more 
frequently, crude weighting factors were devised based on the reported frequency of 
pharmacy visits. Estimates were made of the proportions of the asthmatic population 
visiting pharmacies on various numbers of occasions in the previous year , using 
patient profiles developed in a second study utilising routinely collected drug 
prescription information. These methods have been described e l s ewhe r e . Two 
different weighting factors were devised. The first was based on frequency of 
pharmacy visits to obtain anti-asthma medication and the second on frequency of 
pharmacy visits to have prescriptions filled for (B-agonist drugs. The weighting factors 
were calculated by dividing the population distribution (using the patient profile) by the 
sample distributions (using the questionnaire survey data). 
RESULTS 
1995 Pharmacy Exit Survey 
Six hundred and eighty three purchasers of anti-asthma medications aged 15 years and 
over were asked to fill in the one page written questionnaire. Of these 507 agreed 
giving a response rate of 74.2 percent. Eighteen respondents reported chronic sputum 
production without being diagnosed with asthma and were excluded from further 
analysis. 
The median age of the respondents was 40 years with 47.9 per cent being male 
compared with 36 years and 53.8 per cent respectively for non-respondents. Ninety 
per cent of respondents had been diagnosed with asthma by a doctor compared with 
86 per cent of non-respondents. Forty three per cent of respondents and 40.5 per cent 
of non-respondents reported chronic sputum production. The proportion of non-
respondents obtaining their p-agonist inhalers over the counter on this occasion was 
55.6 per cent compared with 40.2 per cent of respondents. Of the respondents 20.5 
per cent reported that they always, and a further 14.9 per cent reported that they 
usually obtained their P-agonist medications over the counter, while 51.1 per cent 
indicated that they always and 13.5 per cent usually used a prescription to obtain their 
p-agonist medication. 
The respondents were more likely to have had their asthma diagnosed by a doctor (OR 
= 2.09, P = 0.022) and less likely to have obtained their anti-asthma medication 'over 
the counter' on this occasion (OR = 0.54, P = 0.00082). There was no significant 
difference between the respondents and non-respondents in age (P = 0.055), the 
proportion of males (OR = 0.79, P = 0.186), nor the proportion who reported chronic 
cough and sputum (OR = 0.93, P = 0.741). 
Respondent classification as either mainly obtaining their anti-asthmatic medications 
over the counter (the OTC group) or by prescription (the prescription group) was based 
upon their self reported frequency of using a doctors prescription to obtain (3-agonist 
inhalers. Of the 507 respondents 35.4 per cent reported never (20.5 per cent) or 
mostly not (14.9 per cent) using a prescription to obtain inhalers. These respondents 
were classified as mainly obtaining inhalers over the counter. Of the respondents 64.6 
percent reported mostly (13.5 per cent) or always (51.1 per cent) using a prescription 
to obtain inhalers and were hence categorised as mainly obtaining their inhalers by 
prescription. 
A comparison of those respondents predominantly obtaining their |3-agonist inhalers 
over the counter and those using a prescription is shown in Table 1. The OTC group 
was (using at-test) older (P = 0.001), more predominantly male (OR = 1.74, P = 0.004), 
and less likely to report chronic cough and sputum (OR = 0.52, P = 0.006) than the 
prescription group. There was no difference found in the proportion having asthma 
diagnosed by the doctor (OR = 0.98, P = 0.956). 
Of the respondents 69.6 percent reported at least daily use of their p-agonist inhalers 
and 18.1 percent at least five times daily use, 60.6 percent reported wheezing at least 
most days and 28.5 per cent every day, 51.0 per cent reported at least five attacks 
within the previous twelve months and 36.5 per cent reported at least ten attacks. Of 
the respondents 55.0 percent had been admitted to hospital with 'asthma' or'wheeze' 
at least once previously and 13.7 per cent were admitted within the previous year. 
These potential measures of disease severity were compared between the two groups 
(Table 2). The OTC group was less likely to report wheezing at least once per week 
(OR = 0.59; 95% CI = 0.39-0.96; P = 0.0320) as well as at least most days (OR = 0.55; 
95% 01 = 0.36-0.84; P = 0.0052). In the crude analysis, the OTC group was less likely 
to report wheezing every day (OR = 0.52, P = 0.004) however after adjusting for 
differences in age and sex, this difference was not significant (OR = 0.66, 95% CI = 
0.40-1.07; P = 0.0945). 
The prescription group was more likely to have had at least 5 attacks in the last year 
(OR = 0.47, P = 0.001) and to have had at least 10 attacks in the last year (OR = 0.47, 
P = 0.0035). The prescription group was also more likely to have been admitted to 
hospital within the last 12 months for asthma or wheeze (OR = 0.31, P = 0.0009), to use 
their p-agonist puffer at least daily (OR = 0.64, P = 0.0451), and to make more than 25 
visits to the pharmacy in the last 12 months to obtain medication (OR = 0.42, P = 
0.0112). There were no significant differences found in the proportion of people who 
had ever been admitted to hospital for asthma or wheeze (OR = 0.79, P = 0.2746) or 
in those reporting use of (3-agonist puffers at least 5 times daily (OR = 0.79, P = 
0.4122). 
Weighted and crude prevalence estimates of factors related to the management of 
adult asthma for the total population and compared between the OTC group and the 
prescription group are shown in Table 3. 
The OTC group was less likely to have; objective airways measurement by the doctor 
'usually' or 'always' (OR = 0.37; 95% CI = 0.21-0.67; P = 0.0011), possession of a 
written action plan (OR = 0.48; 95% CI = 0.26-0.88; P = 0.0184), regular medical review 
at least once per year (OR = 0.50; 95% CI = 0.27-0.93; P = 0.0297), and regular 
medical review at least twice per year (OR = 0.32; 95% CI = 0.17-0.64; P = 0.0009). 
The proportion of adult asthmatics who use various medications are presented in Table 
4. It is estimated thet 55.0 per cent regularly used inhaled preventative medications 
(corticosteroids or sodium cromoglycate), 10.7 per cent regularly used ipratropium 
bromide, and 9.58 per cent regularly use theophylline. An estimated 5.81 cent 
regularly use oral corticosteroids. Antibiotics were regularly used by 15.3 per cent of 
respondents. 
The OTC group was less likely to regularly use inhaled preventative medications (OR 
= 0.29; 95% CI = 0.16-0.51; P = 0.0001), inhaled corticosteroids (Adjusted OR = 0.35; 
95% CI = 0.20-0.60; P = 0.0001), ipratropium (OR = 0.27; 95% CI = 0.09-0.88; P = 
0.0289) and theophylline (OR = 0.30; 95% CI = 0.11-0.79; P = 0.0151). The OTC 
group was also less likely to have used inhaled corticosteroids (OR = 0.35; 95% CI = 
0.21-0.61; P = 0.0002), ipratropium (OR = 0.44; 95% CI = 0.20-0.94; P = 0.0480) and 
theophylline (OR = 0.43; 95% CI = 0.20-0.94, P = 0.0348) for chest problems at any 
time within the previous six months. 
Changes between 1991 and 1995 
There was a slight but insignificant increase in the proportion of respondents using a 
prescription to obtain p-agonist inhalers from 61.2 per cent in 1991 to 64.6 per cent in 
1995. The 1991 and 1995 respondents were similar in terms of age, sex, proportion 
reporting asthma diagnosis by doctor and chronic cough and sputum for at least three 
months continually. 
The decline in use of p-agonist puffers at least daily from 75.3 per cent in 1991 to 69.6 
per cent in 1995 was of marginal significance (OR = 10.8; 95% CI = 1.00-1.16; P = 
0.0500). Slight reductions were noted on frequency of wheezing, frequency of attacks 
of asthma or wheeze, and in hospital admission within the last 12 months, however 
these improvements were not statistically significant. 
Various non-drug management factors were compared between 1991 and 1995 as 
shown in Table 5. After adjusting for potential measures of disease severity, age and 
sex, the differences between 1991 and 1995 were not statistically significant. 
A comparison between 1991 and 1995 of the use of various medications is shown in 
Table 6. After adjusting for age, sex, and potential measures of disease severity, 
differences in use of inhaled corticosteroids, sodium cromoglycate and theophyllines 
were significant at the 0.05 level. Between 1991 and 1995 it is estimated that regular 
use of inhaled preventative medications increased from 44 per cent to 55 per cent and 
regular use of theophylline declined from 19.0 per cent in 1991 to 9.58 per cent in 
1995. 
No significant clianges were found in the regular use or the use at any time of 
ipratropium, oral corticosteroids, and antibiotics in the previous six months. 
DISCUSSION 
The group predominantly obtaining their 3-agonists over the counter is younger, more 
likely to be male, and less likely to report chronic cough and sputum. Males are less 
likely to go to the doctor than females^^ and hence less likely to obtain a script. There 
are quite large financial benefits from obtaining various anti-asthma medications on 
prescription rather than over the counter for those people holding a concession card. 
3-agonists can be obtained for around a quarter of the price if a script and concession 
card is used. Holders of concession cards are generally older and hence use a script 
in order to obtain the financial benefits. Older people are also more likely to visit a 
general practitioner for problems other than asthma and may obtain scripts for anti-
asthma medications on the same visit. 
The proportion of respondents mainly obtaining their p-agonists by prescription, it is 
similar to the increase noted in a similar study in the Hunter Valley region of NSW in 
1989."'® This group does not have routine review of their asthma as often as the 
prescription group, and are less likely to have a written action plan. It is unlikely that 
there would be an increase in the proportion using a prescription to obtain P-agonist 
inhalers without an increase in the proportion of people having routine medical review.. 
In 1991, the only significant difference in potential disease severity indicators between 
the OTC group and the prescription group were in hospital admissions for asthma or 
wheeze, in 1995 the differences between the OTC group and the prescription group 
were more prominent with regards to disease severity with the prescription group more 
likely to wheeze at least once per week, wheeze most or every day, have at least 5 
attacks of asthma or wheeze in the last year, have at least 10 attacks of asthma or 
wheeze in the last year, to be admitted to hospital within the last 12 months for asthma 
or wheeze and to use a p-agonist inhaler at least daily. These differences were evident 
both in the crude analysis and after adjusting for age and sex. This suggests that the 
gap between the OTC group and the prescription group with regards to disease 
severity may be widening. 
The prescription group has better asthma management practices particularly in relation 
to objective measurement by the doctor, routine medical review, and use of a written 
action plan. The National Asthma Strategy Goals and Targets set by the National 
Asthma Campaign aimed for 21 per cent of people to have a written action plan by the 
year 2000. The baseline for this target is 14 per cent of adults with a written action 
plan."*^ A repeat of this survey in 1993 found the proportion of people with a written 
action plan to be 19.9 per cent.̂ ® Therefore it can be seen that the lllawarra in 1995 
had a reasonably good proportion of adults with written action plans (24.9 per cent) and 
the magnitude of the improvement since 1991 was similar to the National Asthma 
Campaign survey completed slightly earlier. The NAC sampling method was very 
different from that of the lllawarra survey. The NAC survey sampled parents of a 
random sample of primary schoolchildren. It is also possible that the weighting method 
used here in the lllawarra sample does not adequately adjust for the oversampling of 
people with more severe asthma in the OTC group. This methodology is appropriate 
for the prescription group as the weighting factors were developed from prescription 
data. 
The proportion of the respondents reporting objective airways measurement by the 
doctor 'usually' or 'always' (28.4 per cent) and measurement of peak flow at home (27.0 
percent) were still low in 1995. The National Asthma Campaign survey reported that 
in 1993, 29.9 per cent of adult asthmatics had a peak flow meter and 44.4 per cent had 
their lung function measured by the doctor in the previous year. 
The prescription group was more likely to use theophylline at any time in the previous 
six months (OR = 0.43; 95% CI = 0.20-0.94; P = 0.0343). This is a positive result as 
the unsupervised use of theophylline drugs is considered poor management. Overall, 
regular theophylline use decreased from 19.0 percent to 9.6 percent. This reduction 
in the use of theophyllines is not as great as that seen in the second evaluation survey 
done for the National Asthma Campaign. They report a significant reduction in 
theophylline use from 20.5 per cent in 1990 to 3.9 per cent in 1993.̂ ® Differences were 
found in regular use of inhaled corticosteroids and ipratropium between the 'over the 
counter' group and the prescription group both in 1991 and 1995. 
While there were slight improvements in most indicators of disease severity between 
1991 and 1995, these changes were not significant except in relation to the frequency 
of use of p-agonist inhalers. Reductions in the proportion of people using p-agonist 
inhalers between at least a few times a week and at least daily suggest improved 
asthma management. Changes in prescribing which have been made are in 
accordance with the Asthma Management Plan with increased prescribing of inhaled 
corticosteroids and a reduction in the reliance on regular use of p-agonist inhalers. 
These changes have occurred in those people who have a moderate usage of P -
agonist inhalers rather than those with a very high usage of P - a g o n i s t inhalers. 
While most non-medication related management indicators improved slightly between 
1991 and 1995, these changes were not significant. This is possibly due to a lack of 
statistical power and/or that the emphasis of the asthma management plan and local 
initiatives has been on better prescribing. 
There has undoubtedly been an improvement in the prescribing of anti-asthma drugs 
in the lllawarra between 1991 and 1995. Significant improvements in the regular use 
of either inhaled corticosteroids or cromoglycate and a dramatic decrease in use of 
theophylline indicates changes in prescribing in line with the recommendations of the 
asthma management plan. The changes in preventative maintenance therapy have not 
been as great as those put fon/vard in the National Asthma Campaign goals and targets 
document. The target is for 80 per cent of the adult asthmatic population to use 
preventative maintenance therapy by 1996, based upon a baseline measure of 39 per 
cent in 1990.^° The National Asthma Campaign survey reported 38 per cent using 
inhaled corticosteroids or sodium cromoglycate in 1990. This increased to 43 per cent 
by 1993.̂ ^ The increase in the lllawarra from 44 per cent in 1991 to 55 per cent in 1995 
suggests a higher baseline and a greater increase in the lllawarra, however this may 
reflect the different serveillance methods used for the national and lllawarra estimates. 
This increase was significant after adjusting for age, sex and potential measures of 
disease severity (Adjusted OR = 0.87; 95% CI = 0.80-0.95; P = 0.0019). 
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Table 1: Comparison of 'OTC group' and 'Prescription group' 1995 
OTC group Prescription Odds ratio P value 
n=171 group (95% CI) 
n=312 
age (years)* 34.0 (31) 48.5 (50) - 0.001 
sex (M) 56.6%+ 42.8%+ 1.74 0.004 
(1.17-2.60) 
asthma diagnosis 93.7%^ 93.8%** 0.98 0.956 
by doctor (0.39-2.49) 
chronic cough and 32.5%++ 48.1%++ 0.52 0.006 
sputum (0.32-0.85) 








Table 2: Potential measures of disease severity compared between the 'OTC 
group* and the 'Prescription group' 
OTC Prescription Adjusted P value 
group group odds ratio 
n=171 n=309 (95% CI) 
wheeze most or 49.1%* 67.0%^ 0.55 0.0052 
every day (0.36-0.84) 
wheeze every day 20.4%* 33.0%+ 0.66 
(0.40-1.07) 
0.0945 
at least 5 attacks 39.2% 57.6% 0.54 0.0039 
in the last year (0.35-0.80) 
at least 10 attacks 25.7% 42.4% 0.51 0.0035 
last year (0.33-0.80) 
hospital admission 54.8%^ 55.1%^ 0.79 0.2746 
ever for asthma or (0.52-1.20) 
wheeze 
hospital admission 7.14%^ 17.4%^ 0.31 0.0009 






Table 3: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 'OTC group' and the 
'Prescription group' 
Total OTC Prescription Adjusted P 
population group group odds ratio value 
n=482 n=171 n=311 (95% CI) 
objective airways measurement by 27.9% 25.4% 32.2%* 0.37 0.0011 
the doctor 'usually' or 'always' (31.1%) (23.4%) (35.4%) (0.21-0.67) 
peak flow readings at home 28.1% 26.2% 27.8%^ 0.67 0.1597 
(31.0%) (25.7%) (34.0%) (0.38-1.17) 
instruction in inhaler technique 92.8% 92.8% 93.3% 0.87 0.7407 
(93.4%) (91.8%) (94.2%) (0.37-2.01) 
written action plan 24.7% 20.5% 27.6% 0.48 0.0184 
(27.8%) (20.5%) (31.8%) (0.26-0.88) 
regular medical review at least 53.7% 45.3%^ 60.7%^ 0.50 0.0297 
once per year (60.2%) (42.2%) (70.3%) (0.27-0.93) 
regular medical review at least 40.3% 33.6%^ 47.9%^ 0.32 0.0009 





Table 4: Weighted (and crude) prevalence estimates of the use medications 
during the previous six months compared between the 'OTC group' and the 
'Prescription group' 
Total OTC Prescription Adjusted P 
Population group group odds ratio value 
n=483 n = 171 n = 312 (95% CI) 
Regular inhaled corticosteroids or 57.7% 55.9% 59.5% 0.29 0.0001 
cromoglycate (61.9%) (50.3%) (68.3%) (0.16-0.51) 
Regular ipratropium bromide 11.1% 5.96% 14.8% 0.27 0.0289 
(17.6%) (5.26%) (24.4%) (0.09-0.88) 
Regular theophylline 9.49% 8.12% 8.90% 0.30 0.0151 
(12.8%) (7.02%) (16.0%) (0.11-0.79) 
Any inhaled corticosteroids 57.2% 57.0 58.2% 0.35 0.0002 
(60.0%) (51.5%) (64.7%) (0.21-0.61) 
Any sodium cromoglycate 15.7% 16.0 15.4% 0.85 0.6260 
(18.4%) (15.8%) (19.9%) (0.43-1.66) 
Any ipratropium bromide 16.2% 13.6% 18.3% 0.44 0.0480 
(23.0%) (11.1%) (29.5%) (0.20-0.94) 
Any theophylline 14.0% 11.9% 14.7% 0.43 0.0348 
(18.6%) (11.1%) (29.5%) (0.20-0.94) 
Table 5: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 1991 and 1995 
respondents 
1991 1995 Adjusted P value 
n=422 n=490 odds ratio 
(95% CI) 
objective airways 24.1% 28.4%* 0.96 0.4036 
measurements by the doctor (28.2%) (31.4%) (0.88-1.05) 
'usually' or 'always' 
peak flow readings at home 19.5%^ 27.0%^ 0.94 0.2060 
(24.5%) (31.3%) (0.86-1.03) 
instruction in inhaler technique 89.6%^ 90.9% 1.02 0.7658 
(91.9%) (93.1%) (0.88-1.18) 
written action plan 18.4% 24.9% 0.97 0.5807 
(22.8%) (27.6%) (0.89-1.07) 
regular medical review at least 46.5%** 53.9%^+ 0.92 0.1127 
once per year (51.6%) (60.2%) (0.83-1.02) 
regular medical review at least 36.2%** 39.7%++ 0.94 0.2119 







Table 6: Weighted (and crude) prevalence estimates of the use of medications 
during the previous six months compared between 1991 and 1995 
respondents 
1991 1995 Adjusted odds P value 
n = 421 n = 491 ratio 
(95% CI) 
Regular inhaled corticosteroids or 43.7% 55.0% 0.87 0.0019 
cromoglycate (51.1%) (62.1%) (0.80-0.95) 
Regular ipratropium bromide 9.14% 10.7% 0.91 0.1542 
(14.0%) (17.5%) (0.81-1.03) 
Regular theophylline 19.0% 9.58% 1.27 0.0001 
(24.2%) (13.0%) (1.14-1.41) 
Regular oral corticosteroids 6.00% 5.81% 0.98 0.7894 
(8.39%) (8.76%) (0.86-1.13) 
Regular antibiotics 16.0% 15.3% 1.01 0.8277 
(15.2%) (16.3%) (0.91-1.13) 
Any inhaled corticosteroids 47.0% 55.4% 0.94 0.1392 
(54.6%) (60.1%) (0.86-1.02) 
Any sodium cromoglycate 11.2% 13.5% 0.87 0.0117 
(13.5%) (18.7%) (0.77-0.97) 
Any theophylline 25.8% 13.5% 1.27 0.0001 
(32.6%) (18.7%) (1.15-1.40) 
APPENDIX 2 
Contents: 
A2.1 1991 Participants Information Sheet 
A2.2 1991 Pharmacy Exit Survey Questionnaire 
ILLAWARRA PUBLIC HEALTH UNIT 
University of Woliongong lllawarra Area Health Service 
18 Madeline Street 
GWYNNEVILLE NSW 2500 
TELEPHONE: (042) 2 6 4 6 7 7 
(Postal address) 
PO Box 66 
KEIRAVILLE NSW 2500 
FACSIMILE; (042) 264917 
TELL US ABOUT YOUR CHEST 
You may have heard that the lllawarra Pharmacists and 
the lllawarra Public Health Unit are doing a study about 
asthma In the lllawarra. 
As you know asthma Is an important health problem. To 
give the best possible treatment we need to know more about 
who's suffering from chest problems, how badly people are 
suffering and what treatment people are having for their 
asthma at the moment. 
Therefore, we are asking for 3 minutes of your time to 
complete this confidential questionnaire about your 
chest. The questionnaire is on the reverse side of this sheet. 
It is only a page long and for most questions only a tick is 
needed. We do not need your name, only your age and sex. 
It Is important that as many people as possible complete 
these questionnaires. Your help wiii be most appreciated. 
The pharmacist will be pleased to assist you if you have any 
difficulties. 
THANK YOU FOR YOUR COOPERATION. 
CONFIDENTIAL 
^ I ILLAWARRA PHARMACISTS' ASSOCIATION 
'wnrkinQ fnapthpr for n healthier community'" 
Sex: M • F • Age: years 
1. How often do you use this inhaler (puffer) ?, 




a day C 
once a 
] week C 
5-10 times 
) a day C 
a few times 
] pervveek • 
more than 10 
1 limes a day • 
2. How often do you v/heeze? svery day • i 11 • II 
'x; - p i v v e g i i ® 1 










4. Has a doctor or other health worker ever shown you how io use your 
inhaler correctly? 
Yes O f ; | | | | | i | | | B | 
If YE5, who? (ea: codor. pnarmacisi, physio, nurse, hospfial casualiv) [ 
5. How many attacks of asthma or wheezing have 
you had in the last year? 
none 
• 
1 - 4 
• 
5 - 10 
• 
more than 10 
• 
6. How ouen does your doctor measure your 
breathing with a peak flow meter or other device? 
never 
; | | | | i | l | i | 
^siSccasiofialiyl 
: | | | | | | j | i j : 
/•-ahvays 
7. Do you measure your own peak flow at home? Yes D No • 
8. Do you usually visit a doctor about your chest: 
a._ When^your;chest;:ts;ii^ 
b. .Fqr:reGii iar.r^ i t t i i l ® : - ^ -
; :ivyics or more ^ 
''a::ye3r D 
9. Have you been admitted to hospital with asthma or wheezing? 
( l i ck o n e ) no, never • 
yes, not in 
last year • 
yes, in 
last year • 
1 10. Do you have a written plan of what to do when you have an attack? Yes • 1 No O 
11. Durina the last 6 months which of the following medications have you taken 
for your chest? (For each group, you may tick none, one or two boxes.) 
1 
s. Ventolin, Respolin, Berotec, Bricanyl, Alupent 
b. Atrovent 
c. Intal 
d. Becoiide, Becloforte or Aldecin 
e. Nuelin, Theodur, Elixophyliin, Choledyl, Brondecon 
f. Cortisone, Celestone, Prednisolone 
g. Antihistamines eg: Avil, Polaramine, Zadine, Demazin, Teldane 
h. Antibiotics eg; Penicillin, Abbocillin, Amoxyl, Augmentin, Doryx, Cecior, 
Mysieclin, Vibramycin, Vibra-Tabis, Kelfex, Bactrim, Septrin, etc 



















12. How many times during the last 12 months have you visited a -
pharmacy to obtain medication for your chest? 
•  'if: 5-10 • 
1 - 2 • 
11 ' 25 O 
3 
more 
than 25 D 
APPENDiy 
Contents: 
A3.1 1995 Participants Information Sheet 
A3.2 1995 Pharmacy Exit Survey Questionnaire 
University of Wollongong Illawarra Area Health Service 
^ I L L A W A R R A " A R ^ 
18 Madeline Street 
GWYNNEVILLE NSW 2500 
Telephone: (042) 26 4677 
(Postal Address) 
PO Box 66 
KErRAVDLLE NSW 2500 
FacsimOe: (042) 264917 
TELL US ABOUT YOUR CHEST 
You may have heard that the Illawarra Pharmacists and the 
Illawarra Public Health Unit are doing a study about asthma In 
the liiawarra. We conducted this study first In Aug-Sept 1991. 
This present study Is Intended to be a repeat of that study to 
see If asthma managment has Improved. 
As you know asthma Is an Important health problem. To give 
the best possible treatment we need to know more .about who's 
suffering from chest problemsiliow bldly people are suffering and 
what treatment people are having for their asthma at the moment. 
Therefore^ we are asking forjs minutes of your time to 
complete this confidential questionnaire about your chest. The 
questionnaire is on the reverse side of this sheet. It is only a page 
Jong and for most questions only a tick is needed. We do not need, 
"your nameî ^̂ only your age and sex. You are under no obligation to 
cqmplete the questionnaire though we would appreciate you doing 
;:S0. 
it is Important that as many people as possible complete these 
questionnaires. Your help wiil be most appreciated. The 
/pharmacist will be pleased to assist you if you have any difficulties. 
;:lf you have any;enquiries regarding the conduct of the research 
please contact t̂he Secretary of the University of Wollongong 
{-iuman ResearC: Ethics Committee on (042) 213 457. 
I understand the data collected will be used for a repeal study Into asthma 
mnagniM and I consent for the data to be used In UiBwanner. 
If you wish to take part in this research please sign below:: 
"working together for a healthier community 
PHARMACY EXIT SURVEY 
SEX: M • F • Age: _years 
1. How often do you use an inhaler (pu f fe r )?Vento i in . Respoiin. 
Berotec, Bricanyl, Alupent,Asmol.Serevent o n l y 
less than 
onceAveek • 
1-4 times a 
day • 
once a week • 
5-10 times 
a day • 
a few times 
per week • 
more than 10 
times a day • 
1— r^::-; 
2. How often do you wheeze? ' • 
every day • most days • about once a 
week • 
less than once a 
week • 
i 3. Do you use a doctor's prescription .to obtain this 
' inhaler J . 
never • mostly not • mostly • aKvays • 
^ 4. Has your doctor or other health worker ever shown you how to use your 
i inhaler correctly? 
Yes No 
• 
If YES who ? (e.a. doctor, pharmacist, physio, nurse, hospital casualty): 
5. How many attacks of asthma or wheezing have 







more than 10 
• 
6. How often does your doctor measure your 










7 Do you measure your own peak flow meter at home? 
Yes • No • 
8. Do you usually visit a doctor about your chest: 
a. When your chest is causing problems ? 
b. For regular review, even if your chest is not causing problems ? 
If Yes to b, - how often ? Less than 
once a yearO 
Yes • 
Yes • 
Once a year • 
No • 
No • 
Twice or more a 
year • 
9. Have you been admitted to hospital with asthma or 
wheezina? (tick one) 
no, never • yes, not in last 
year • 
yes, in last y e a r D 
10.DO you have a written plan of what to do when you have an attack? 
Yes • No • 
H.Dijnna the last 6 months which of the following medications have you 
taken? (tick one or more) 
a. Ventolin, Respoiin, Berotec, Bricanyl, Alupent,Asmol.Serevent 
b. Atrovent, Tilade, Fiixotide 
c. Intal 
d. Becotide, Becloforte, Aldecin or Pulmicort 
e. Nuelin, Theodur, Elixophyllin, Choledyl or Brondecon 
f. Cortisone, Celestone or Prednisolone 
q. Antihistamines e.g.iAvil, Polaramine, Zadine, Demazin,TeIdane . , 
h Antibiotics e.g.: Penicillin, Abbociilin, Amoxyl, Augmentin, Doryx, Ceclor, Mys.eclm, 
Vibramydn,Vibra-Tabs, Keflex, Bactrim, Septrin, Rulide, Erythromycin etc. 







f • g • 
h • 









12.H0W many times during the last 12 months have you visited 






more than 25 • 
13.During the last 12 months how many times have you been 
to a community pharmacy to have a prescription filled for 







more than 25 • 
APPENDIX 4 : Results of reanalysis of 1991 Pharmacy Exit Survey 
Contents: 
Table A4.1: Comparison of questionnaire respondents and non-respondents 
Table A4.2: Comparison of 'OTC group' and 'Prescription group' 
Table A4.3: Potential measures of disease severity compared between the 'OTC group' 
and the 'Prescription group' 
Table A4.4: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 'OTC group' and the 'Prescription 
group' 
Table A4.5: Weighted (and crude) prevalence estimates of the use medications 
regularly during the previous six months compared between the 'OTC group' and the 
'Prescription group' 
Table A4.6: Weighted (and crude) prevalence estimates of use of medications at any 
time during the previous six months compared between the 'OTC group' and the 
'Prescription group' 
Table A4.1: Comparison of questionnaire respondents and non-respondents 
Respondents Non- Odds Ratio P value 
respondents (95% CI) 
age (years)* 42.2 (40) 38.2 (32) - 0.036 
n = 429 n = 107 
sex(M) 53.3% 54.1% 0.97 0.891 
n = 422 n = 98 (0.61-1.54) 
asthma 95.4% 87.2% 3.01 0.005 
diagnosis by n = 324 n = 94 (1.27-7.14) 
doctor 
chronic cough 46.2% 44.7% 1.26 0.391 
and sputum n = 238 n = 74 (0.72-2.22) 
obtained 42.6% 64.6% 0.41 0.00013 
medication n = 312 n = 99 (0.25-0.67) 
'over-the-
counter' 
* Mean ages reported with median ages in parentheses. Difference tested using a t-
test. 
Table A4.2: Comparison of 'OTC group' and 'Prescription group' 
OTC group Prescription Odds ratio P value 
group (95% CI) 
age (years)* 35.1 (32) 46.6 (47) _ 0.001 
n = 164 n = 259 
sex (M) 62.2% 48.8% 1.73 0.007 
n = 164 n = 252 (1.13-2.63) 
asthma diagnosis 94.4% 95.9% 0.73 0.554 
by doctor n = 126 n = 194 (0.23-2.31) 
chronic cough and 31.9% 54.5% 0.39 0.001 
sputum n = 91 n = 145 (0.22-0.70) 
* Mean ages reported with median ages in parentheses. Difference tested using a t-
test. 
Table A4.3: Potential measures of disease severity compared between the 'OTC 
group' and the 'Prescription group' 
OTC Prescription Crude Adjusted P 
group group odds ratio odds ratio value 
(95% CI) (95% CI) 
wheeze at least 76.3% 79.7% 0.82 0.83 0.4628 
once per week n = 156 n = 246 (0.49-1.37) (0.39-1.04) 
wheeze most or 57.1% 67.5% 0.64 0.75 0.1984 
every day n = 156 n = 246 (0.41-0.99) (0.48-1.16) 
wheeze every day 21.8% 34.2% 0.54 0.64 0.0700 
n = 156 n = 246 (0.33-0.87) (0.50-1.38) 
at least 5 attacks 52.8% 54.7% 0.93 1.01 0.9662 
in the last year n = 163 n = 256 (0.61-1.40) (0.66-1.53) 
at least 10 attacks 35.6% 42.2% 0.76 0.85 0.4548 
last year n = 163 n = 256 (0.49-1.16) (0.55-1.31) 
hospital admission 43.2% 55.0% 0.62 0.64 0.0370 
ever for asthma or n = 162 n = 258 (0.41-0.94) (0.42-0.97) 
wheeze 
hospital admission 7.41% 19.4% 0.33 0.37 0.0046 
within the last 12 n = 162 n = 258 (0.16-0.67) (0.18-0.73) 
months 
use of beta- 68.8% 79.3% 0.57 0.77 0.2903 
agonist puffer at n = 160 n = 256 (0.36-0.92) (0.48-1.24) 
least daily 
use of beta- 10.6% 18.4% 0.53 0.71 0.2916 
agonist puffer at n = 162 n = 258 (0.28-0.99) (0.37-1.34) 
least 5 times daily 
more than 25 9.94% 25.8% 0.32 0.43 0.0070 
visits to pharmacy n = 161 n = 256 (0.17-0.59) (0.23-0.79) 
for medication 
Table A4.4: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 'OTC group' and the 
'Prescription group' 
Total OTC Prescription Crude Adjusted P 
population group group odds ratio odds ratio value 
(95% CI) (95% CI) 
objective airways 24.1% 14.7% 31.2% 0.35 0.44 0.0107 
measurement by the (28.4%) (16.6%) (35.9%) (0.21- (0.24-
doctor 'usually' or n = 163 n = 256 0.59) 0.83) 
'always' 
peak flow readings 19.5% 16.6% 22.6% 0.62 0.59 0.0942 
at home (24.4%) (19.1%) (27.7%) (0.37- (0.32-
n = 162 n = 256 1.02) 1.09) 
instruction in inhaler 89.6% 90.9% 88.6% 0.69 1.28 0.6008 
technique (91.9%) (90.2%) (93.0%) (0.33- (0.51-
n = 163 n = 256 1.48) 3.23) 
written action plan 18.4% 14.9% 21.2% 0.57 0.65 0.1805 
(23.0%) (17.1%) (26.6%) (0.34- (0.35-
n = 158 n = 256 0.96) 1.22) 
regular medical 46.5% 26.5% 58.5% 0.21 0.31 0.0003 
review at least once (51.6%) (28.6%) (66.0%) (0.12- (0.17-
per year n = 119 n = 191 0.35) 0.59) 
regular medical 36.2% 19.6% 45.0% 0.21 0.35 0.0017 
review at least twice (43.6%) (21.9%) (57.1%) (0.12- (0.18-
per year n = 119 n = 191 0.36) 0.67) 
Table A4.5: Weighted (and crude) prevalence estimates of the use medications 
regularly during the previous six months compared between the 'OTC group' and 
the 'Prescription group' 
Total 
population 
n = 423 
OTC 
group 
n = 164 
Prescription 
group 













































































































Table A4.6: Weighted (and crude) prevalence estimates of use of medications at 
any time during the previous six months compared between the 'OTC group' and 
the 'Prescription group' 
Total 
population 
n = 428 
OTC 
group 
n = 164 
Prescription 
group 










































































































APPENDiX jS; Tables of weighted and crude prevalence estimates of management 
factors and use of medication. Weighting factors are based upon self reported 
frequency of pharmacy visits to obtain anti-asthma medication. 
Contents: 
Table A5.1: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 'OTC group' and the 'Prescription 
group' 
Table A5.2: Weighted (and crude) prevalence estimates of the use medications 
regularly during the previous six months compared between the 'OTC group' and the 
'Prescription group' 
Table A5.3: Weighted (and crude) prevalence estimates of use of medications at any 
time during the previous six months compared between the 'OTC group' and the 
'Prescription group' 
Table A5.1: Weighted (and crude) prevalence estimates of factors related to the 















objective airways 28.4% 21.3% 32.5% 0.56 0.37 0.0011 
measurement by the (31.1%) (23.4%) (35.4%) (0.36- (0.21-
doctor 'usually' or n = 171 n = 308 0.87) 0.67) 
'always' 
-
peak flow readings 27.0% 21.7% 29.8% 0.69 0.67 0.1597 
at home (31.0%) (25.7%) (34.0%) (0.45- (0.38-
n = 171 n = 306 1.08) 1.17) 
instruction in inhaler 90.9% 89.6% 92.0% 0.69 0.87 0.7407 
technique (93.4%) (91.8%) (94.2%) (0.32- (0.37-
n = 171 n = 311 1.51) 2.01) 
written action plan 24.9% 18.9% 28.7% 0.55 0.48 0.0184 
(27.8%) (20.5%) (31.8%) (0.35- (0.26-
n = 171 n = 311 0.88) 0.88) 
regular medical 53.9% 43.2% 60.7% 0.31 0.50 0.0297 
review at least once (60.2%) (42.2%) (70.3%) (0.19- (0.27-
per year n = 135 n = 239 0.49) 0.93) 
regular medical 39.7% 25.2% 48.4% 0.25 0.32 0.0009 
review at least twice (48.4%) (27.4%) (60.3%) (0.15- (0.17-
per year n = 135 n = 239 0.40) 0.64) 
Table A5.2: Weighted (and crude) prevalence estimates of the use medications 
regularly during the previous six months compared between the 'OTC group' and 
the 'Prescription group' 
Total 
population 
n = 483 
OTC 
group 
n = 171 
Prescription 
group 













































































































Table A5.3: Weighted (and crude) prevalence estimates of use of medications at 
any time during the previous six months compared between the 'OTC group' and 
the 'Prescription group' 
Total 
population 
n = 477 
OTC 
group 
n = 171 
Prescription 
group 










































































































APPENDIX 6.- Comparison of 1991 and 1995 factors related to management with 
frequency of p-agonist use removed from the logistic regression model. 
Contents: 
Table A6.1: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 1991 and 1995 respondents 
Table A6.1: Weighted (and crude) prevalence estimates of factors related to the 
management of adult asthma compared between the 1991 and 1995 respondents 









measurements by the 




n = 422 
28.4% 
(31.4%) 










n = 421 
27.0% 
(31.3%) 










n = 421 
90.9% 
(93.1%) 






written action plan 18.4% 
(22.8%) 
n = 417 
24.9% 
(27.6%) 






regular medical review 
at least once per year 
46.5% 
(51.6%) 
n = 314 
53.9% 
(60.2%) 






regular medical review 
at least twice per year 
36.2% 
(43.3%) 
n = 314 
39.7% 
(48.6%) 
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